<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="ppub"/></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS161032</article-id><article-id pub-id-type="doi">10.1101/2021.12.17.473223</article-id><article-id pub-id-type="archive">PPR434689</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group><subj-group subj-group-type="europepmc-category"><subject>Covid-19</subject></subj-group></article-categories><title-group><article-title>ACE2-containing defensosomes serve as decoys to inhibit SARS-CoV-2 infection</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ching</surname><given-names>Krystal L.</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>de Vries</surname><given-names>Maren</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Gago</surname><given-names>Juan</given-names></name><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Dancel-Manning</surname><given-names>Kristen</given-names></name><xref ref-type="aff" rid="A4">4</xref><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Sall</surname><given-names>Joseph</given-names></name><xref ref-type="aff" rid="A4">4</xref><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Rice</surname><given-names>William J.</given-names></name><xref ref-type="aff" rid="A4">4</xref><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Barnett</surname><given-names>Clea</given-names></name><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><name><surname>Liang</surname><given-names>Feng-Xia</given-names></name><xref ref-type="aff" rid="A4">4</xref><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Thorpe</surname><given-names>Lorna E.</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Shopsin</surname><given-names>Bo</given-names></name><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A8">8</xref><xref ref-type="aff" rid="A9">9</xref></contrib><contrib contrib-type="author"><name><surname>Segal</surname><given-names>Leopoldo N.</given-names></name><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><name><surname>Dittmann</surname><given-names>Meike</given-names></name><xref ref-type="aff" rid="A2">2</xref><xref ref-type="corresp" rid="CR1">*</xref></contrib><contrib contrib-type="author"><name><surname>Torres</surname><given-names>Victor J.</given-names></name><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A9">9</xref><xref ref-type="corresp" rid="CR1">*</xref></contrib><contrib contrib-type="author"><name><surname>Cadwell</surname><given-names>Ken</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A10">10</xref><xref ref-type="corresp" rid="CR1">*</xref></contrib></contrib-group><aff id="A1"><label>1</label>Kimmel Center for Biology and Medicine at the Skirball Institute, New York University Grossman School of Medicine, New York, NY, 10016</aff><aff id="A2"><label>2</label>Department of Microbiology, New York University Grossman School of Medicine, New York, NY, 10016</aff><aff id="A3"><label>3</label>Division of Epidemiology, Department of Population Health, New York University Grossman School of Medicine, New York, NY, 10016</aff><aff id="A4"><label>4</label>Division of Advanced Research Technologies, New York University Langone Health, New York, NY, 10016</aff><aff id="A5"><label>5</label>The Cryo–Electron Microscopy Laboratory at New York University Langone Health, New York, NY, 10016</aff><aff id="A6"><label>6</label>The Microscopy Laboratory at New York University Langone Health, New York, NY, 10016</aff><aff id="A7"><label>7</label>Division of Pulmonary and Critical Care Medicine, New York University Grossman School of Medicine, New York, New York, 10016</aff><aff id="A8"><label>8</label>Division of Infectious Diseases and Immunology, Department of Medicine, New York University Grossman School of Medicine, New York, NY, 10016</aff><aff id="A9"><label>9</label>Antimicrobial-Resistant Pathogens Program, NYU Langone Health, New York, NY 10016</aff><aff id="A10"><label>10</label>Division of Gastroenterology and Hepatology, Department of Medicine, New York University Grossman School of Medicine, New York, NY, 10016</aff><author-notes><corresp id="CR1">
<label>*</label><bold>Co-corresponding authors</bold>: Meike Dittmann, Victor J. Torres, and Ken Cadwell <email>ken.cadwell@nyulangone.org</email> (K.C.); <email>Victor.torres@nyulangone.org</email> (V.J.T.); <email>Meike.Dittman@nyulangone.org</email> (M.D.)</corresp></author-notes><pub-date pub-type="nihms-submitted"><day>18</day><month>01</month><year>2023</year></pub-date><pub-date pub-type="preprint"><day>23</day><month>12</month><year>2021</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://europepmc.org/downloads/openaccess</ali:license_ref><license-p>This preprint is made available via the <ext-link ext-link-type="uri" xlink:href="https://europepmc.org/downloads/openaccess">Europe PMC open access subset</ext-link>, for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original preprint source.</license-p></license></permissions><abstract><p id="P1">Extracellular vesicles of endosomal origin, exosomes, mediate intercellular communication by transporting substrates with a variety of functions related to tissue homeostasis and disease. Their diagnostic and therapeutic potential has been recognized for diseases such as cancer in which signaling defects are prominent. However, it is unclear to what extent exosomes and their cargo inform the progression of infectious diseases. We recently defined a subset of exosomes termed defensosomes that are mobilized during bacterial infection in a manner dependent on autophagy proteins. Through incorporating protein receptors on their surface, defensosomes mediated host defense by binding and inhibiting pore-forming toxins secreted by bacterial pathogens. Given this capacity to serve as decoys that interfere with surface protein interactions, we investigated the role of defensosomes during infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of COVID-19. Consistent with a protective function, exosomes containing high levels of the viral receptor ACE2 in bronchioalveolar lavage fluid from critically ill COVID-19 patients was associated with reduced ICU and hospitalization times. We found ACE2+ exosomes were induced by SARS-CoV-2 infection and activation of viral sensors in cell culture, which required the autophagy protein ATG16L1, defining these as defensosomes. We further demonstrate that ACE2+ defensosomes directly bind and block viral entry. These findings suggest that defensosomes may contribute to the antiviral response against SARS-CoV-2 and expand our knowledge on the regulation and effects of extracellular vesicles during infection.</p></abstract></article-meta></front><body><sec id="S1" sec-type="intro"><title>Introduction</title><p id="P2">Exosomes are a subgroup of single membraned vesicles 40-120 nm in diameter secreted by virtually every cell type. Cargo molecules ranging from non-coding RNAs to proteins involved in signal transduction are incorporated during exosome biogenesis, which involves exocytosis of endosomal structures [<xref ref-type="bibr" rid="R1">1</xref>]. As such, exosomes mediate intercellular communication events involved in cell proliferation, migration, and cancer [<xref ref-type="bibr" rid="R2">2</xref>]. A role in host defense is supported by the finding that exosomes can deliver nucleic acids and other immunogenic moieties from infected cells that elicit interferon responses or promote antigen presentation by target cells [<xref ref-type="bibr" rid="R3">3</xref>–<xref ref-type="bibr" rid="R8">8</xref>]. However, how exosomes are regulated in response to infections remains unclear. A better understanding may inform strategies that seek to use extracellular vesicles as biomarkers or therapeutic agents for infectious disease.</p><p id="P3">In our previous work, we identified exosomes involved in host defense termed defensosomes that mediated protection against bacterial pore-forming toxins that kill target cells, such as α-toxin produced by <italic>Staphylococcus aureus</italic> [<xref ref-type="bibr" rid="R9">9</xref>]. Recognition of bacterial DNA by toll-like receptor 9 (TLR9) led to increased production of defensosomes decorated by ADAM10, the host cell surface target of α-toxin, in a manner dependent on ATG16L1 and other components of the membrane trafficking pathway of autophagy. We further demonstrated that ADAM10<sup>+</sup> defensosomes serve as decoys that bind α-toxin and prevent cytotoxicity in cell culture and animal models [<xref ref-type="bibr" rid="R9">9</xref>]. Therefore, in addition to mediating intercellular communication by transferring signaling molecules between cells, exosomes can also promote host defense through a surface interaction with bacterial proteins. Whether defensosomes are deployed during a viral infection remains unclear.</p><p id="P4">Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the respiratory virus responsible for the ongoing global COVID-19 pandemic, can cause life threatening tissue injury to the lung as well as extrapulmonary symptoms that are less understood [<xref ref-type="bibr" rid="R10">10</xref>]. Entry into host cells mainly depends on the binding of receptor-binding domain (RBD) of SARS-CoV-2 spike (S) protein to host receptor ACE2. The affinity of SARS-CoV-2 spike for ACE2 is 5 times higher than that of SARS-CoV spike [<xref ref-type="bibr" rid="R11">11</xref>], and 1,000 times higher than hemagglutinin of Influenza A for sialic acid [<xref ref-type="bibr" rid="R12">12</xref>]. Given this dependence on a high affinity cell surface interaction for viral entry, we hypothesized ACE2 containing defensosomes would inhibit SARS-CoV-2 infection through the binding of the spike protein.</p></sec><sec id="S2" sec-type="results"><title>Results</title><sec id="S3"><title>Increased proportion of ACE2+ exosomes in human BAL fluid correlates with reduced time in the ICU</title><p id="P5">Few studies, if any, have analyzed exosomes in mucosal tissues of patients during an ongoing infection. This is especially true in the setting of SARS-CoV-2 infection where access to lower airway samples were limited due to concerns about possible risks for health care professionals [<xref ref-type="bibr" rid="R13">13</xref>–<xref ref-type="bibr" rid="R20">20</xref>]. In the airways, <italic>ACE2</italic> expression exists as a gradient, with the highest levels in the nasal passageway, down to the lower airways where it is exclusively expressed on Type II pneumocytes [<xref ref-type="bibr" rid="R21">21</xref>]. To determine whether ACE2+ exosomes are generated and are present in the respiratory tract, we analyzed bronchioalveolar lavage fluid (BALF) samples from 80 critically ill COVID-19 patients [<xref ref-type="bibr" rid="R22">22</xref>] using biochemical fractionation to enrich for exosomes followed by flow cytometry [<xref ref-type="bibr" rid="R9">9</xref>]. All patients in our cohort were admitted to the intensive care unit (ICU) due to respiratory failure requiring invasive mechanical ventilation and tested positive for SARS-CoV-2 infection [<xref ref-type="bibr" rid="R22">22</xref>]. Applying stringent gating criteria for exosomes, we observed remarkable interindividual variation in the proportion of exosomes with surface ACE2 and the levels of ACE2 present on each exosome measured by mean fluorescence intensity (MFI) (<xref ref-type="fig" rid="F1">Fig. 1A</xref>, <xref ref-type="supplementary-material" rid="SD4">Supp. Fig. 1A-C</xref>). We found that 10 patients had at least two-fold higher exosomes levels in their BALF compared to the mean exosome levels from the other patients. These data suggest that there is variation between individuals in how much ACE2 is loaded into each exosome as well as how many ACE2+ exosomes are produced by each person.</p><p id="P6">We then asked whether level of ACE2 on exosomes or proportion of ACE2+ exosomes correlate with clinical parameters such as patient age, sex, disease severity, infection status, and other comorbidities linked to SARS-CoV-2 infection such as diabetes or hypertension. 76.2% of the patients were male, mostly nonwhite (53.8%), with a mean age of 62 years (SD, 14.2). Hypertension and diabetes were reported in 52.5% and 38.3% of patients, respectively (<xref ref-type="supplementary-material" rid="SD4">Supp. Table 1</xref>). Two patients were excluded from analysis because they were not within 3 standard deviations from the mean (47.96 days) for length of stay in the ICU. As a sensitivity analysis, we also ran the regressions using ACE2 MFI as a predictor of ICU stay outcome, resulting in the same trends in the covariates (<xref ref-type="supplementary-material" rid="SD4">Supp. Table 3</xref>). Compiling the information regarding the proportion of exosomes that contain ACE2+ in patient BALF, we ran different models using clinical data to test whether there was any association with ACE2+ exosomes and length of stay in the ICU, as there was no correlation with mortality. We performed a linear model and a negative binomial model to test this relationship, and we controlled for age, gender, culture results of BAL and blood, diabetes, and hypertension. We also included in a sensitivity analysis model an interaction term between gender, sex, and hypertension, as they are usually correlated. We expressed the coefficients without interactions for simplicity because the estimates did not significantly change. The linear model resulted in negative correlation between length of stay in the ICU and the proportion of ACE2+ exosomes found in the BALF (<xref ref-type="table" rid="T1">Table 1</xref>, <xref ref-type="fig" rid="F1">Fig. 1B</xref>). The negative binomial model predicted similar results (<xref ref-type="supplementary-material" rid="SD4">Supp. Table 2</xref>). To account for increased length of stay in the ICU due to complications or subsequent infections, we also used ventilation days as an outcome, and found that proportion of ACE2+ exosomes remained a significant predictor (<xref ref-type="supplementary-material" rid="SD4">Supp. Tables 4-5</xref>).</p><p id="P7">These analyses uncovered a threshold where patients with a proportion of ACE2+ exosomes lower than the mean (38.78%) generally have increased lengths of stay in both the ICU and hospital, and increased days on a ventilator (<xref ref-type="fig" rid="F1">Fig. 1D</xref>, <xref ref-type="supplementary-material" rid="SD4">Supp. Fig. 1D</xref>). Individuals with diabetes (or both diabetes and hypertension) clustered below the average proportion of ACE2+ exosomes (<xref ref-type="fig" rid="F1">Fig. 1D</xref>), suggesting common comorbidities may influence the proportion of ACE2+ exosomes. Individuals with hypertension have been shown to have reduced levels of circulating ACE2 with the adverse consequence of increased concentration of the vasoconstricting molecule Angiotensin II due to activation of ACE [<xref ref-type="bibr" rid="R23">23</xref>]. However, neither diabetes nor hypertension were associated with statistically significant differences in ACE2 levels on exosomes (<xref ref-type="supplementary-material" rid="SD4">Supp. Fig. 1E-F</xref>). Altogether, these data show that the proportion of ACE2+ exosomes and level of ACE2 on individual exosomes in BALF from patients with COVID-19 are highly variable, and their increased presence are associated with a reduction in the hospitalization days.</p></sec><sec id="S4"><title>Defensosomes are produced in response to SARS-CoV-2 and antiviral sensors</title><p id="P8">We previously showed that exosomes are induced by TLR9 activation in response to bacterial DNA or synthetic agonist CpG-A. It was unclear whether innate immune ligands generated during RNA viral infections affect exosome production. Although SARS-CoV-2 is not predicted to directly activate DNA sensors, damage during respiratory tract infection can lead to production of oxidized mitochondrial DNA (ox-mtDNA) [<xref ref-type="bibr" rid="R24">24</xref>, <xref ref-type="bibr" rid="R25">25</xref>], which is known to be a potent ligand for TLR9 [<xref ref-type="bibr" rid="R26">26</xref>]. Stimulation with ox-mtDNA increased exosome production in A549 cells, but this was not observed with sheared genomic DNA (gDNA) or DNA fragments without any oxidized bases (<xref ref-type="fig" rid="F2">Fig. 2A</xref>). We also tested CpG-B, which can activate TLR9, but unlike CpG-A, lacks a phosphodiester backbone and poorly induces interferons (IFNs) [<xref ref-type="bibr" rid="R27">27</xref>]. CpG-B stimulation failed to elicit exosomes from A549 cells (<xref ref-type="fig" rid="F2">Fig. 2B</xref>). SARS-CoV-2 has been shown to indirectly activate the cytosolic DNA sensing pathway dependent on cGAS/STING [<xref ref-type="bibr" rid="R28">28</xref>]. However, ligands for cGAS/STING (2’3’-cGAMP and 3’3’-cGAMP) failed to induce exosomes (<xref ref-type="fig" rid="F2">Fig. 2B</xref>).</p><p id="P9">It is possible that IFNs generated downstream of TLR9 activation mediate exosome production. Stimulation of A549 cells with IFN-β induced exosomes in a concentration dependent manner, where at higher concentrations, the number of exosomes began to decrease (<xref ref-type="fig" rid="F2">Fig. 2C</xref>), which may be due to ISGylation and degradation of the compartment where exosomes are generated [<xref ref-type="bibr" rid="R29">29</xref>]. IFN-α and IFN-λ2 also induced exosomes (<xref ref-type="fig" rid="F2">Fig. 2D-E</xref>). As expected, IFN-β failed to elicit exosomes from triple-knockout (TKO) A549 cells that lack receptors necessary for recognition of all three major classes of IFNs (IFNAR, IFNGR, and IFNLR) (<xref ref-type="fig" rid="F2">Fig. 2F</xref>). In contrast, TKO A549 cells were still able to produce exosomes in response to CpG-A (<xref ref-type="fig" rid="F2">Fig. 2G</xref>). Thus, IFN stimulation is sufficient to induce exosome production, but are not required downstream of nucleic acid sensing.</p><p id="P10">SARS-CoV-2 infection generate viral ssRNA and dsRNA that may serve as signals to induce exosomes. When transfected into cells, low and high molecular weight versions of the dsRNA mimetic poly I:C preferentially activate the cytosolic RNA sensors RIG-I and MDA-5, respectively, but we found that neither induced exosomes (<xref ref-type="fig" rid="F2">Fig. 2H</xref>. In A549 cells, the endosomal dsRNA sensor TLR3 is expressed at low levels; IFN-α treatment induces TLR3 to functionally active levels, allowing A549 cells to become sensitive to untransfected poly I:C [<xref ref-type="bibr" rid="R30">30</xref>]. Following pretreatment with IFNα for 24hr, A549 cells produced 10-20-fold more exosomes in response to poly I:C without a transfection agent (<xref ref-type="fig" rid="F2">Fig. 2I</xref>). A549 cells do not express the endosomal ssRNA sensors TLR7 or TLR8. We found that ectopic expression of TLR7 led to exosome induction upon stimulation with a synthetic agonist, R848 (<xref ref-type="fig" rid="F2">Fig. 2J</xref>).</p><p id="P11">Given that multiple innate immune ligands induce exosome production, we asked whether ACE2+ exosomes are induced by SARS-CoV-2 infection. We found that SARS-CoV-2 infection of A549 cells ectopically expressing ACE2 (A549<sup>ACE2+</sup>) induced robust production of ACE2+ exosomes (<xref ref-type="fig" rid="F2">Fig. 2K</xref>). Similar to our observations with bacteria, SARS-CoV-2-induced exosome production was impaired by <italic>ATG16L1</italic> knockdown (<xref ref-type="fig" rid="F2">Fig. 2K</xref>). Therefore, the enhanced production of ACE2+ exosomes display a key hallmark of defensosomes – induced in response to infectious cues in a manner dependent on ATG16L1.</p></sec><sec id="S5"><title>ACE2+ defensosomes neutralize SARS-CoV-2 virions</title><p id="P12">Our finding that ACE2+ exosomes in patient BALF display an inverse correlation with length of hospital stay raised the possibility that they play a role during viral infection akin to our previous description of defensosomes during bacterial toxinosis. Therefore, we tested whether addition of exosomes can protect Vero E6 cells, which are highly susceptible to SARS-CoV-2 infection (<xref ref-type="fig" rid="F3">Fig. 3A</xref>). Exosomes were isolated from A549<sup>ACE2+</sup> cells (<xref ref-type="fig" rid="F3">Fig. 3B</xref>) and mixed with human SARS-CoV-2 USA WA1/2020 isolate at an MOI of 0.01. We included a polyclonal neutralizing antibody targeting spike (nAb) as a positive control. Addition of ACE2+ exosomes led to a dose-dependent reduction in viral nucleoprotein (NP) staining by immunofluorescence microscopy at 24 hr post-infection (<xref ref-type="fig" rid="F3">Fig. 3C-D</xref>, <xref ref-type="supplementary-material" rid="SD4">Supp. Fig. 2A</xref>), whereas ACE2-exosomes from untransduced control A549s failed to inhibit infection. Also, addition of the microvesicle fraction that does not contain exosomes (5000x<italic>g</italic>) did not decrease infection levels (<xref ref-type="fig" rid="F3">Fig. 3C</xref>). We also tested neutralization in human airway epithelial cultures (HAECs), an air-liquid (ALI) interface model that contains all major cell types found in the bronchial epithelium (basal, ciliated, secretory), organized in pseudostratified architecture [<xref ref-type="bibr" rid="R31">31</xref>]. Addition of ACE2+ exosomes mixed with SARS-CoV-2 to the apical side (“lumen”) blocked infection of HAECs, while ACE2-exosomes did not show any significant effect (<xref ref-type="fig" rid="F3">Fig. 3E</xref>, <xref ref-type="supplementary-material" rid="SD4">Supp. Fig. 2B</xref>).</p><p id="P13">We next tested whether inducing exosome production protects against viral infection without the need of adding exogenous exosomes from donor cells. We found that pre-treatment with CpG-A, which we confirmed induces exosome production by Vero E6 cells in a manner dependent on ATG16L1 (<xref ref-type="fig" rid="F3">Fig. 3F-G</xref>), led to a reduction in cells infected with SARS-CoV-2 (<xref ref-type="fig" rid="F3">Fig. 3H</xref>). Removing the exosome-containing supernatant prior to infection led to similar levels of SARS-CoV-2 infection as unstimulated cells (<xref ref-type="fig" rid="F3">Fig. 3H</xref>, <xref ref-type="supplementary-material" rid="SD4">Supp. Fig. 2C</xref>). This protection is unlikely to be mediated by IFNs, as Vero E6 cells cannot produce IFNs [<xref ref-type="bibr" rid="R32">32</xref>, <xref ref-type="bibr" rid="R33">33</xref>]. Together, these results show that defensosomes can inhibit SARS-CoV-2 infection.</p></sec><sec id="S6"><title>ACE2+ defensosomes directly interact with SARS-CoV-2</title><p id="P14">We next used electron microscopy techniques to visualize the interactions between SARS-CoV-2 virions and defensosomes. Viral particles with predicted spherical shape and uniform size of 80-100 nm in diameter were detected by negative stain imaging in control suspensions containing SARS-CoV-2 virions alone (<xref ref-type="fig" rid="F4">Fig. 4A</xref>) [<xref ref-type="bibr" rid="R34">34</xref>]. With the addition of exosomes, we detected structures with the characteristic collapsed morphology of exosomes clustered around particles with virion morphology. The difficulty in distinguishing exosomes and virions due to their similar shape and size precluded quantification of the data. Therefore, we used immuno-gold labeling in which exosomes and SARS-CoV-2 virions were identified by an anti-CD63 antibody coupled to 18 nm gold particle and an anti-NP antibody coupled to a nanogold particle (1.4 nm), respectively (<xref ref-type="fig" rid="F4">Fig 4B</xref>). We observed an enrichment of CD63 labeling around SARS-CoV-2 virions when incubated with ACE2+ exosomes, but not ACE2-exosomes (<xref ref-type="fig" rid="F4">Fig. 4C</xref>). The pronounced clustering of CD63 in the ACE2+ exosome-virus mixtures may be indicative of multiple exosomes bound to the virions, however, we cannot definitively conclude the number of exosomes due to the lack of contrast of the exosome membranes.</p><p id="P15">Lastly, we applied cryo-electron microscopy and tomography to confirm these associations between SARS-CoV-2 virions and ACE2+ exosomes. Virions were easily distinguished by the presence of protrusions that resembled the club-like head of the spike protein and exosomes were larger single membraned vesicles, spherical or ellipsoid in shape. Focusing on the area between the viral and exosome membranes, we were able to visualize an elongated structure resembling the post-fusion form of spike and ACE2 in some tomograms (<xref ref-type="supplementary-material" rid="SD4">Supp. Fig. 3A, 3B</xref>, <xref ref-type="supplementary-material" rid="SD1">Videos 1</xref>-<xref ref-type="supplementary-material" rid="SD2">2</xref>). Tomographic reconstruction also captured several virions around larger exosomes as well as potential virions inside an exosome (<xref ref-type="supplementary-material" rid="SD3">Video 3</xref>). Collectively, these data demonstrate that the presence of ACE2 on exosomes increases binding and clustering of virions.</p></sec></sec><sec id="S7" sec-type="discussion"><title>Discussion</title><p id="P16">Our analyses of an inpatient cohort of COVID-19 patients revealed ACE2 levels on exosomes in BALF can display striking interindividual variability, and that a high proportion of ACE2+ exosomes, especially those with increased surface levels, are associated with reduced hospital stay. Although it is unclear whether ACE2+ exosomes are a marker or have a causative role in recovery from SARS-CoV-2 infection, our cell culture experiments indicate that they can inhibit viral infection by serving as defensosomes. The ability to produce sufficient numbers of defensosomes is key to providing optimal protection <italic>in vitro,</italic> and thus, understanding the factors that contribute to variable exosome production at mucosal surfaces during SARS-CoV-2 infection and other conditions will be of great interest. Transcriptional regulation and cleavage by proteases such as ADAM10 and ADAM17 [<xref ref-type="bibr" rid="R35">35</xref>] may also explain heterogeneity in ACE2+ exosomes. Other unanswered questions include how ACE2+ exosome release affects the availability of ACE2 in the tissue and whether this impacts acute injury to the lung, another function of this critical enzyme involved in cardiovascular processes [<xref ref-type="bibr" rid="R36">36</xref>]. Also, we focused on surface protein interactions, but it is important to consider other ways SARS-CoV-2 infection can be impacted by exosomes, which have been shown to facilitate the transfer of viral and cellular components to target cells with either pro-viral or antiviral consequences depending on the pathogen [<xref ref-type="bibr" rid="R37">37</xref>–<xref ref-type="bibr" rid="R39">39</xref>].</p><p id="P17">Infection by SARS-CoV-2 and other coronaviruses leads to formation of structures resembling autophagosomes [<xref ref-type="bibr" rid="R40">40</xref>–<xref ref-type="bibr" rid="R42">42</xref>], double-membrane vesicles generated during autophagy that target intracellular material to the lysosome for degradation [<xref ref-type="bibr" rid="R43">43</xref>]. Several SARS-CoV-2 proteins inhibit formation of autophagosomes or prevent the acidification of lysosomes and endosomes, promoting viral egress from the cell [<xref ref-type="bibr" rid="R44">44</xref>–<xref ref-type="bibr" rid="R49">49</xref>]. Although viruses such as SARS-CoV-2 evade autophagy-mediated degradation during intracellular replication, our results suggest extracellular virions may be subject to neutralization by defensosomes generated through an autophagy-like process dependent on ATG16L1. In this context, it is notable that defensosomes are induced by innate immune activation of TLRs that require a signaling endosome [<xref ref-type="bibr" rid="R50">50</xref>, <xref ref-type="bibr" rid="R51">51</xref>], which may coincide with the location from which exosomes are generated. The termination of TLR7 signaling is mediated by the packaging of TLR7 into exosomes via a ESCRT independent mechanism involving ALIX and the recruitment of syntenin-1 by UNC93B1 [<xref ref-type="bibr" rid="R52">52</xref>], providing precedence for coupling viral RNA recognition with extracellular vesicle trafficking. Cells that produce significant amounts of IFN in response to sensing of viral PAMPs through TLRs, such as plasmacytoid dendritic cells [<xref ref-type="bibr" rid="R53">53</xref>], could play an important role in initiating early protection by activating cells in distal tissues to release exosomes.</p><p id="P18">Several clinical trials are underway for exosome-based therapies against various cancers and kidney disease [<xref ref-type="bibr" rid="R54">54</xref>–<xref ref-type="bibr" rid="R56">56</xref>]. The advantage of strategies involving exosomes includes their scalability, stability in biofluids, and ability to be engineered to carry desired receptors and even deliver drugs. Our results support a broad innate antimicrobial function for defensosomes that includes defense against viral disease. An improved understanding of defensosome regulation may inform clinical applications.</p></sec><sec id="S8" sec-type="materials | methods"><title>Materials And Methods</title><sec id="S9"><title>Cohort of critically ill COVID-19 patients.</title><p id="P19">The characteristics of this cohort have recently been described [<xref ref-type="bibr" rid="R22">22</xref>]. Briefly, we enrolled adults (&gt;18 years old) admitted to the intensive care unit due to respiratory failure requiring invasive mechanical ventilation with confirmed diagnosis of SARS-CoV-2 infection by reverse transcriptase polymerase chain reaction (RT-PCR). Lower airway samples (bronchoalveolar lavage, BAL) were obtained during clinically indicated bronchoscopy performed for airway clearance or for percutaneous tracheostomy placement. Surviving subjects signed informed consent to participate in this study while samples and metadata from subjects who died or were incapacitated were de-identified and included in this study. All patients or their legal representative agreed to participate via our NYU IRB approved protocol (IRB no. s16-00122/01598). The study protocol was approved by the Institutional Review Board of New York University.</p></sec><sec id="S10"><title>Cell Culture and lentivirus production</title><p id="P20">A549 cells were purchased from ATCC. A549<sup>ACE2</sup> cells were generated using lentiviral transduction of a human ACE2 cDNA expressing plasmid (backbone: pLV-EF1a-IRES-Puro (Addgene 85132) as previously described [<xref ref-type="bibr" rid="R31">31</xref>]. TLR7+ A549 were generated by lentiviral transduction of pcDNA3-TLR7-YFP (a gift from Doug Golenbock (Addgene plasmid # 13022; <ext-link ext-link-type="uri" xlink:href="http://n2t.net/addgene:13022">http://n2t.net/addgene:13022</ext-link> ; RRID:Addgene_13022)). A549<sup>ACE2</sup> cells were selected using 1μg/ml puromycin. Cells were cultured with 10% Dulbecco’s modified Eagle medium (DMEM (Gibco), 10% fetal calf serum (FCS), 1% non-essential amino acids (NEAA), 1% Penicillin/Streptomycin) and filtered using a 0.22μm filter unit (Millipore). Vero E6 cells were purchased from ATCC (cat. No. CLR-1586) and maintained in same media as A549 cells, but including 10mg/mL Amphotericin B. 293FTs were maintained in same media as A549 cells. Lentivirus was produced by transfecting 10cm plate of 293FTs with 10μg of plasmid using Lipofectamine 3000. Media was exchanged the next day and lentivirus was collected the following day. 1mL lentivirus was used to transduce A549 cells using Polybrene (Millipore). TKO (IFNAR1/IFNLR/IFNGR1) A549 cells were generously provided by Marco Binder at the German Cancer Research Center (DKFZ), Heidelberg, Germany [<xref ref-type="bibr" rid="R57">57</xref>].</p><p id="P21">Stimulations were done with 0.5μM CpG-ODN 2216 (Class A) or CpG-ODN 2006 (Class B) (Invivogen), 1μg/mL R848 (Invivogen), human IFN-β (R&amp;D), IFN-λ2 (cat. No. 8417-IL-025, R&amp;D), IFNα (cat. No 11200-2, R&amp;D), 1μg/mL 3’3’-cGAMP, 1ug/mL 2’3’-cGAMP (Invivogen), and PolyI:C LMW and HMW with and without LyoVec (Invivogen).</p></sec><sec id="S11"><title>BSL3</title><p id="P22">Plaque and neutralization assays were performed in the BSL3 facility of NYU Grossman School of Medicine, in accordance with its Biosafety Manual and Standard Operating Procedures.</p></sec><sec id="S12"><title>Plaque Assay</title><p id="P23">Viral titers were determined by plaque assay. Vero E6 cells were seeded into 12-well plates to reach confluency the next day. When confluent, cells were washed twice with PBS (Ca/Mg+) before the infection with 1:10 serial dilutions of the samples for 1 h at 37°C. At 1 h post virus addition, virus was removed, cells were washed again twice with PBS (Ca/Mg+), and overlay-medium was added (minimal essential medium (MEM), 1.5μg/ml Trypsin-TPCK, 1.6% Oxoid-Agar, 1% Pen-Strep, 1% GlutaMax, 20 mM HEPES, 0.4% BSA, and 0.24% NaHCO3). At 72 h post infection, the cells were fixed by adding 10% formalin solution for 24 hrs. After fixation, overlay was removed and cells were stained with crystal violet solution (0.1 % crystal violet in 1.9% Ethanol and 19% Methanol in cell culture grade H2O) for at least 30 min. Plates were rinsed once with H2O before determining the viral titer.</p></sec><sec id="S13"><title>Virus Amplification</title><p id="P24">All SARS-CoV-2 stock preparations and subsequent infection assays were performed in the CDC/USDA-approved biosafety level 3 (BSL-3) facility in compliance with NYU Grossman School of Medicine guidelines for BSL-3. SARS-CoV-2 isolate USA-WA1/2020, deposited by the Centers for Disease Control and Prevention, was obtained through BEI Resources, NIAID, NIH (cat. no. NR-52281; GenBank accession number MT233526). The USA-WA1/2020 stock was passaged twice in Vero E6 cells to generate a passage 6 working stock (1.0E+06 PFU/ml) for our studies.</p></sec><sec id="S14"><title><italic>In vitro</italic> Neutralization Assay</title><p id="P25">3.2x10<sup>4</sup> Vero E6 cells were seeded in black 96-flat well with clear bottom plates 24hr before infection. SARS-CoV2 was mixed 1:1 v/v with exosomes in infection media (DMEM, 10% HEPES, 10% NEAA) and allowed to bind for 1hr at 37°C. Heat-inactivated plasma (56°C for 1 hour) from a convalescent patient was used as a positive control. Confluent Vero cells were then infected with this exosome-virus mixture. At 24 hpi, plates were fixed with 10% formalin solution for 30-45 min and then washed with dH2O. Plates were permeabilized with 0.1% Triton-X 100, blocked with 1% BSA/PBS and stained for SARS-CoV-2 N mouse monoclonal SARS-CoV-2 anti-N antibody 1C7 (1:1000, kind gift of Thomas Moran) overnight at 4°C. Plates were then incubated with Alexa Fluor 647 goat anti-mouse Ab (1:2000) and DAPI (1:2000) at 37°C for 1hr. After 3 washes with PBS, plates were imaged using the Cell Insight CX7 LZR high-content screening platform. Images were analyzed and quantified with HCS Navigator software.</p></sec><sec id="S15"><title>Infection and immunofluorescence of HAECs</title><p id="P26">Maintenance of HAECs were done as described in [<xref ref-type="bibr" rid="R31">31</xref>]. At 48 h prior to infection, 6-8-week-old HAECs were washed apically twice for 30 min each with prewarmed PBS (Ca/Mg+). At 1 hr prior to infection, cultures were washed apically twice for 30 min each with prewarmed PBS. Each culture was infected with a viral dilution containing with 1.35E+05 PFU with or without exosomes for 2 h at 37°C. The inoculum was removed, and the cultures were washed three times with prewarmed PBS. For each washing step, PBS was added to the apical surface, and cultures were incubated at 37°C for 30 min before the PBS was removed. The third wash was collected and stored at −80°C for titration by plaque assay on Vero E6 cells. Infectious particles were collected every 24 hr (up to 72 hr) by adding 60 μl of prewarmed PBS, incubating at 37°C for 30 min, and washes were stored at −80°C. Wells were fixed by submerging in 10% formalin for 24 h and washed three times with PBS before analysis by immunofluorescence. Fixed HAECs were quenched 50 mM NH<sub>4</sub>Cl (in PBS), permeabilized using a solution of, 0.1% Saponin, and blocked with 2% BSA. Cultures were stained with anti-SARS nucleocapsid protein antibody which cross reacts with SARS-CoV-2 N (1:1000, cat. no. 200-401-A50; Rockland) and goat-anti-rabbit Alexa Fluor 488 and DAPI.</p></sec><sec id="S16"><title>Mitochondrial DNA generation</title><p id="P27">Short mitochondrial DNA fragments (221bp) were amplified from gDNA from A549 cells with and without 8-Oxo-2’-deoxyguanosine-5’-Triphosphate (TriLink Biotechnologies) using GoTaq Mastermix. Forward primer: 5’-CCCCACAAACCCCATTACTAAACCCA-3’. Reverse: 5’-TTTCATCATGCGGAGATGTTGGATGG-3’. Fragments were isolated using Quick PCR Clean Up kit (Qiagen). Genomic DNA fragments were generated by sonicating genomic DNA isolated from A549 cells (Qiagen Blood and Tissue DNeasy kit) using genomic DNA tips (20g).</p></sec><sec id="S17"><title>shRNA knockdown</title><p id="P28">Lentivirus based knockdown of human <italic>ATG16L1</italic> (<italic>5</italic>’-ACTGTAGCTTTGCCGTGAATG-<italic>3</italic>’) was performed using MISSION shRNA constructs (Sigma-Aldrich) and psPAX2 packaging system. psPAX2 was a gift from Didier Trono (Addgene plasmid # 12260). Lentivirus expressing shRNAs were produced by DNA transfection using Lipofectamine 3000 (Thermo Fisher). Transduction was performed using Polybrene (Millipore) and selection was done using 1μg/mL puromycin.</p></sec><sec id="S18"><title>Flow Cytometry</title><p id="P29">Exosomes pellets were stained with 100μl of an antibody cocktail in 1X PBS (Corning) containing anti-CD9 (human HI9a, mouse MZ3), anti-CD63 (human H5C6, mouse NVG-2), anti-CD81 antibodies (human 5a6, mouse Eat-2) from Biolegend, and anti-human ACE2 (R&amp;D Biosystems cat no. FABAF9332R) at 1:100 for 1hr at 4°C, rocking. Exosomes were stained with PKH67 cell linker dye (Sigma). Exosomes were washed with 1X PBS once and ultracentrifuged at 100,000x<italic>g</italic> for 1.5hr. The exosome pellet was resuspended in PBS. Cells and exosomes were analyzed using a Beckman Coulter Cytoflex S cytometer at the slowest flow rate.</p></sec><sec id="S19"><title>Exosome Isolation</title><p id="P30">Cell culture supernatants were spun at 500x<italic>g</italic> for 10min, followed by a 10,000x<italic>g</italic> spin for 10min. Supernatants were passed through a 0.22μm filter (Millex-GP PES). Supernatants were washed with 1x PBS and pelleted by ultracentrifugation at 100,000x<italic>g</italic> for 1.5hrs. Exosomes used for neutralization were resuspended in viral media (10% DMEM, 1% HEPES, 1% PenStrep) and transferred to a non-TC round bottom 96-well plate (Corning).</p><p id="P31">All human BAL samples were processed into cellular and supernatant fractions before freezing for further analysis. Exosomes were isolated from 200μl of thawed acellular BAL fluid and fixed to a final concentration of 4% PFA before being removed from the BSL-3 facility. Samples were washed with PBS and ultracentrifuged at 100,000xg for 1.5hr before staining for flow cytometry analysis.</p></sec><sec id="S20"><title>Negative Stain, Immunogold Labeling, and Cryo Electron Tomography</title><p id="P32">Exosomes isolated from A549 and A549<sup>ACE2</sup> cells stimulated with Bafilomycin A1 were mixed with SARS-CoV-2 and allowed to bind for 1hr at 37°C in the BSL3 before being fixed with 4% PFA. Suspensions of SARS-CoV-2/exosomes were ultracentrifuged once at 100,000 x <italic>g</italic> to pellet, and then resuspended in PBS before processing for TEM imaging.</p><p id="P33">Negative stain of exosome-virus mixtures involved deposit of 3μl of 4% paraformaldehyde fixed exosomes on glow discharged carbon copper grids. Grids were stained with 1% uranyl acetate and were imaged under FEI Talos L120C TEM and photographed with a Gatan (<italic>4k</italic> x 4<italic>k</italic>) OneView camera (Gatan Inc., Pleasanton, CA.)</p><p id="P34">For double immunogold labeling, exosome -virus mixtures in PBS were fixed to final concentration of 4% PFA and placed on glow-discharged formvar-carbon copper grids for 20min. Staining was done as follows: Grids were washed with PBS (pH 7.4) twice for 2 min each followed by incubation with PBS/Glycine 50mM for 3 min. Grids were permeabilized and blocked with 0.1% Saponin/1% cold-water fish skin gelatin (Perm buffer) for 10 min and first stained with anti-human CD63 (Abcam, ab59479) antibody (1:10) in Perm buffer for 1.5hr. Grids were washed 6x with PBS with 0.1% Saponin for 2 min, and then incubated with 18nm gold conjugated anti-mouse antibody (18nm colloidal gold AffiniPure goat anti-mouse IgG (H+L), Jackson ImmunoResearch Laboratories, Inc., West Grove, PA), in Perm buffer for 30min. After washing with PBS, grids were fixed in 2% PFA in PBS for 5 min.</p><p id="P35">Grids were washed with PBS and then incubated in PBS/50mM glycine for 3min to quench the unbounded aldehyde group. The grids were incubated with anti-NP antibody (1:100) in perm buffer for 1.5 hr followed by anti-mouse Fab’ nanogold (1:250, Nanoprobe, New York) in perm buffer for 30min. Grids were fixed in 1% glutaraldehyde in PBS for 5min, washed with distilled water, followed by washes with 0.02M sodium citrate buffer (pH 7.0). The silver enhancement is done using HQ Silver enhancement kit (#2012, HQ Silver, Nanoprobe, New York) for 9 minutes, and rinsed with ddH2O. Finally, grids were contrasted with 3% uranyl acetate and embedded with 2% methylcellulose in a ratio of 1 to 9.</p><p id="P36">Immunogold and nanogold double labeling was quantified using ImageJ software (NIH).</p></sec><sec id="S21"><title>CryoEM Sample Collection</title><p id="P37">Samples for CryoET were plunge frozen in liquid ethane with a VitroBot Mark IV (Thermo Fisher) at 20°C at 100% humidity on C-flat (Protochips, Morrisville NC) 1.2/1.3 grids with 80s easyGlow (Ted Pella Inc, Redding CA) glow discharge. All images were acquired on the Talos Arctica (Thermo Fisher) housed at NYU. Images were taken at 200 kV with a Gatan K3 imaging system (Gatan Inc, Pleasanton CA) collected at 28,000X nominal magnification. The calibrated super-resolution pixel size of 0.7040 Å was used for processing.</p><p id="P38">Micrographs were collected using Leginon [<xref ref-type="bibr" rid="R58">58</xref>, <xref ref-type="bibr" rid="R59">59</xref>] at a dose rate of 11.21 e<sup>-</sup>/Å<sup>2</sup>/s with a total exposure of 3.50 seconds, for an accumulated dose of 39.23 e<sup>-</sup>/Å<sup>2</sup>. Intermediate frames were recorded every 0.07 seconds for a total of 50 frames per micrograph. Frames were aligned using Motioncor2 [<xref ref-type="bibr" rid="R60">60</xref>].</p><p id="P39">Tilt series were collected using SerialEM [<xref ref-type="bibr" rid="R61">61</xref>] at a dose rate of 11.21 e<sup>-</sup>/Å<sup>2</sup>/s with a total exposure of 0.25 second for an accumulated dose of 2.79 e<sup>-</sup>/Å<sup>2</sup> per tilted image. Intermediate frames were recorded every 0.05 seconds for a total of 5 frames per micrograph. Movies were collected in super-resolution mode. Tilt series were acquired in a bidirectional pattern starting from -18°, with a range from -60° to 60° in 3° step with a total dose of 114e<sup>-</sup>/Å<sup>2</sup>.</p></sec><sec id="S22"><title>Tilt series processing</title><p id="P40">Frames were aligned using Warp [<xref ref-type="bibr" rid="R62">62</xref>], binned to the physical pixel size of 1.408 Å, and constructed into a tilt series stack for further processing. Micrographs within each tilt series were aligned with EMAN2 [<xref ref-type="bibr" rid="R63">63</xref>] and constructed into a tomogram at binning 4 (5.63 Å/pixel) using Fourier inversion. Tomograms were denoised using Topaz [<xref ref-type="bibr" rid="R64">64</xref>]. Denoised tomograms were inspected using IMOD [<xref ref-type="bibr" rid="R65">65</xref>] and clipped to appropriate size. Movies were made from selected tomograms using ImageJ. Automated segmentation was performed using EMAN2 to segment membranes, and further 3D rendering and refinement of Spike proteins was done manually on ORS Dragonfly (Object Research Systems, Quebec, Canada).</p></sec><sec id="S23"><title>Patient correlation analysis</title><p id="P41">Anonymized data contained patient demographics, medications prescribed during hospital admission, vitals upon entry to the hospital, reported comorbidities, spike and RBD antibody titers, and blood and lung culture results. All analyses were performed in R Studio (version 1.4.1717).</p></sec><sec id="S24"><title>Statistical Analyses</title><p id="P42">Statistical analyses were performed using GraphPad Prism 9.0 (GraphPad Software, San Diego, California USA; <ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com/">https://www.graphpad.com/</ext-link>). All graphs show the mean and standard error of the mean (SEM). An unpaired two-tailed t-test was used to evaluate differences between two groups with Welch’s correction. One way ANOVA with Dunnett’s post-test was used to evaluate experiments involving groups of 3 or more. Two-way ANOVA with Dunnett’s or Šidák’s post-test was used to evaluate groups with more than one variable. Correlation was analyzed using Pearson r. For each test, a p-value &lt;0.05 is considered statistically significant. Clinical data was analyzed using R-studio. We performed descriptive analysis extracting data from EHR for these patients and summarizing this data with R. Linear model was used with the outcome as length of stay in the ICU. As a sensitivity analysis, we also performed a negative binomial model. with ACE2 MFI as a predictor instead of % ACE2 positivity, which yielded the same results.</p></sec></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Video 1</label><media xlink:href="EMS161032-supplement-Video_1.avi" mimetype="video" mime-subtype="x-msvideo" id="d16aAdEbB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD2"><label>Video 2</label><media xlink:href="EMS161032-supplement-Video_2.avi" mimetype="video" mime-subtype="x-msvideo" id="d16aAdEcB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD3"><label>Video 3</label><media xlink:href="EMS161032-supplement-Video_3.avi" mimetype="video" mime-subtype="x-msvideo" id="d16aAdEdB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD4"><label>Supplementary Figures And Tables</label><media xlink:href="EMS161032-supplement-Supplementary_Figures_And_Tables.pdf" mimetype="application" mime-subtype="pdf" id="d16aAdEeB" position="anchor"/></supplementary-material></sec></body><back><ack id="S25"><title>Acknowledgements</title><p>We thank the Office of Science &amp; Research High-Containment Laboratories at NYU Grossman School of Medicine for their support in the completion of this research and the NYU Langone Health’s Microscopy Laboratory and CryoEM Core. We also thank Marco Binder’s group for providing the TKO A549 cells, Rachel Prescott for maintaining HAECs, and Stephen T. Yeung and Yonghua Li for thawing and handling BALF samples. <xref ref-type="supplementary-material" rid="SD4">Supplemental figure 4A</xref> was created using BioRender.</p><sec id="S26"><title>Funding</title><p>This work was in part funded by NIH grants DK093668 (K.C.), HL123340 (K.C.), AI130945 (K.C.), AI140754 (K.C.), DK124336 (K.C.), AI121244 (K.C. and V.J.T.), AI099394 (V.J.T.), AI105129 (V.J.T.), AI137336 (V.J.T.), AI133977 (V.J.T.), AI140754 (V.J.T.), AI149350 (V.J.T.), AI143639 (M.D.), AI139374 (M.D.), CA244775 (L.N.S., NCI/NIH). Further funding was provided by Faculty Scholar grant from the Howard Hughes Medical Institute (K.C.), Crohn’s &amp; Colitis Foundation (K.C.), Kenneth Rainin Foundation (K.C.), Judith &amp; Stewart Colton Center of Autoimmunity (K.C.), NSF Graduate Research Fellowship (K.L.C.), NYU Grossman School of Medicine COVID-19 seed research funds to V.J.T, and a pilot funding from the NYU Langone Health Antimicrobial-resistant Pathogen Program (B.S. and V.J.T.). NYU Langone’s Cytometry and Cell Sorting Laboratory and Microscopy Laboratory are partially supported by NYU Cancer Center support grant P30CA016087.</p></sec></ack><fn-group><fn id="FN1" fn-type="con"><p id="P43"><bold>Author Contributions</bold></p><p id="P44">K.L.C., M.D., V.J.T., and K.C. conceived and designed the study. K.L.C., M.D.V., J.G., C.B. performed the experiments and analyzed the data. K.L.C., K.D., and J.S., performed and analyzed the electron microscopy data. F.-X.L provided assistance TEM and W.J.R. performed and analyzed CryoEM experiments. L.N.S provided BAL samples and patient metadata, L.N.S. and B.S. provided guidance on analyzing patient data. L.E.T. provided advice on statistical analyses of patient metadata. K.L.C., J.G. M.D.V., M.D., V.J.T., and K.C. interpreted the data. K.L.C., V.J.T., and K.C. wrote the paper with input from all authors.</p></fn><fn id="FN2" fn-type="conflict"><p id="P45"><bold>Declaration of Interests</bold></p><p id="P46">K.C. has received research support from Pfizer, Takeda, Pacific Biosciences, Genentech, and Abbvie. K.C. has consulted for or received honoraria from Vedanta, Genentech, and Abbvie. K.C. holds U.S. patent 10,722,600 and provisional patent 62/935,035 and 63/157,225. V.J.T. receives research support from Janssen Biotech Inc. V.J.T has consulted for Janssen Research &amp; Development, LLC and have or received honoraria from Genentech and Medimmune. V.J.T. is an inventor on patents and patent applications filed by New York University, which are currently under commercial license to Janssen Biotech Inc. Janssen Biotech Inc. provides research funding and other payments associated with a licensing agreement.</p></fn></fn-group><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathieu</surname><given-names>M</given-names></name><name><surname>Martin-Jaular</surname><given-names>L</given-names></name><name><surname>Lavieu</surname><given-names>G</given-names></name><name><surname>Thery</surname><given-names>C</given-names></name></person-group><article-title>Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication</article-title><source>Nat Cell Biol</source><year>2019</year><volume>21</volume><issue>1</issue><fpage>9</fpage><lpage>17</lpage><comment>Epub 2019/01/04</comment><pub-id pub-id-type="pmid">30602770</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalluri</surname><given-names>R</given-names></name><name><surname>LeBleu</surname><given-names>VS</given-names></name></person-group><article-title>The biology, function, and biomedical applications of exosomes</article-title><source>Science</source><year>2020</year><volume>367</volume><issue>6478</issue><pub-id pub-id-type="pmcid">PMC7717626</pub-id><pub-id pub-id-type="pmid">32029601</pub-id><pub-id pub-id-type="doi">10.1126/science.aau6977</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>Schorey</surname><given-names>JS</given-names></name></person-group><article-title>Extracellular vesicles deliver Mycobacterium RNA to promote host immunity and bacterial killing</article-title><source>EMBO reports</source><year>2019</year><volume>20</volume><issue>3</issue><fpage>e46613</fpage><pub-id pub-id-type="pmcid">PMC6399609</pub-id><pub-id pub-id-type="pmid">30683680</pub-id><pub-id pub-id-type="doi">10.15252/embr.201846613</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nandakumar</surname><given-names>R</given-names></name><name><surname>Tschismarov</surname><given-names>R</given-names></name><name><surname>Meissner</surname><given-names>F</given-names></name><name><surname>Prabakaran</surname><given-names>T</given-names></name><name><surname>Krissanaprasit</surname><given-names>A</given-names></name><name><surname>Farahani</surname><given-names>E</given-names></name><etal/></person-group><article-title>Intracellular bacteria engage a STING-TBK1-MVB12b pathway to enable paracrine cGAS-STING signalling</article-title><source>Nature Microbiology</source><year>2019</year><volume>4</volume><issue>4</issue><fpage>701</fpage><lpage>13</lpage><pub-id pub-id-type="pmcid">PMC6433288</pub-id><pub-id pub-id-type="pmid">30804548</pub-id><pub-id pub-id-type="doi">10.1038/s41564-019-0367-z</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sisquella</surname><given-names>X</given-names></name><name><surname>Ofir-Birin</surname><given-names>Y</given-names></name><name><surname>Pimentel</surname><given-names>MA</given-names></name><name><surname>Cheng</surname><given-names>L</given-names></name><name><surname>Abou Karam</surname><given-names>P</given-names></name><name><surname>Sampaio</surname><given-names>NG</given-names></name><etal/></person-group><article-title>Malaria parasite DNA-harbouring vesicles activate cytosolic immune sensors</article-title><source>Nature Communications</source><year>2017</year><volume>8</volume><issue>1</issue><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="pmcid">PMC5719353</pub-id><pub-id pub-id-type="pmid">29215015</pub-id><pub-id pub-id-type="doi">10.1038/s41467-017-02083-1</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>VL</given-names></name><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>Bryant</surname><given-names>BR</given-names></name><name><surname>Schorey</surname><given-names>JS</given-names></name></person-group><article-title>Exosomes function in antigen presentation during an in vivo Mycobacterium tuberculosis infection</article-title><source>Scientific Reports</source><year>2017</year><volume>7</volume><issue>1</issue><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="pmcid">PMC5338015</pub-id><pub-id pub-id-type="pmid">28262829</pub-id><pub-id pub-id-type="doi">10.1038/srep43578</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Utsugi-Kobukai</surname><given-names>S</given-names></name><name><surname>Fujimaki</surname><given-names>H</given-names></name><name><surname>Hotta</surname><given-names>C</given-names></name><name><surname>Nakazawa</surname><given-names>M</given-names></name><name><surname>Minami</surname><given-names>M</given-names></name></person-group><article-title>MHC class I-mediated exogenous antigen presentation by exosomes secreted from immature and mature bone marrow derived dendritic cells</article-title><source>Immunology Letters</source><year>2003</year><volume>89</volume><issue>23</issue><fpage>125</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">14556969</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hui</surname><given-names>WW</given-names></name><name><surname>Emerson</surname><given-names>LE</given-names></name><name><surname>Clapp</surname><given-names>B</given-names></name><name><surname>Sheppe</surname><given-names>AE</given-names></name><name><surname>Sharma</surname><given-names>J</given-names></name><name><surname>Del Castillo</surname><given-names>J</given-names></name><etal/></person-group><article-title>Antigen-encapsulating host extracellular vesicles derived from Salmonella-infected cells stimulate pathogen-specific Th1-type responses in vivo</article-title><source>PloS Pathogens</source><year>2021</year><volume>17</volume><issue>5</issue><elocation-id>e1009465</elocation-id><pub-id pub-id-type="pmcid">PMC8101724</pub-id><pub-id pub-id-type="pmid">33956909</pub-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1009465</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keller</surname><given-names>MD</given-names></name><name><surname>Ching</surname><given-names>KL</given-names></name><name><surname>Liang</surname><given-names>FX</given-names></name><name><surname>Dhabaria</surname><given-names>A</given-names></name><name><surname>Tam</surname><given-names>K</given-names></name><name><surname>Ueberheide</surname><given-names>BM</given-names></name><etal/></person-group><article-title>Decoy exosomes provide protection against bacterial toxins</article-title><source>Nature</source><year>2020</year><volume>579</volume><issue>7798</issue><fpage>260</fpage><lpage>4</lpage><comment>Epub 2020/03/07</comment><pub-id pub-id-type="pmcid">PMC7519780</pub-id><pub-id pub-id-type="pmid">32132711</pub-id><pub-id pub-id-type="doi">10.1038/s41586-020-2066-6</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Zuo</surname><given-names>Z</given-names></name><name><surname>Kang</surname><given-names>S</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Xia</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Multi-organ Dysfunction in Patients with COVID-19: A Systematic Review and Meta-analysis</article-title><source>Aging Dis</source><year>2020</year><volume>11</volume><issue>4</issue><fpage>874</fpage><lpage>94</lpage><comment>Epub 2020/08/09</comment><pub-id pub-id-type="pmcid">PMC7390520</pub-id><pub-id pub-id-type="pmid">32765952</pub-id><pub-id pub-id-type="doi">10.14336/AD.2020.0520</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walls</surname><given-names>AC</given-names></name><name><surname>Park</surname><given-names>Y-J</given-names></name><name><surname>Tortorici</surname><given-names>MA</given-names></name><name><surname>Wall</surname><given-names>A</given-names></name><name><surname>McGuire</surname><given-names>AT</given-names></name><name><surname>Veesler</surname><given-names>D</given-names></name></person-group><article-title>Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein</article-title><source>Cell</source><year>2020</year><volume>181</volume><issue>2</issue><fpage>281</fpage><lpage>92</lpage><elocation-id>e6</elocation-id><pub-id pub-id-type="pmcid">PMC7102599</pub-id><pub-id pub-id-type="pmid">32155444</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.058</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>X</given-names></name><name><surname>Coombs</surname><given-names>PJ</given-names></name><name><surname>Martin</surname><given-names>SR</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Xiao</surname><given-names>H</given-names></name><name><surname>McCauley</surname><given-names>JW</given-names></name><etal/></person-group><article-title>Receptor binding by a ferret-transmissible H5 avian influenza virus</article-title><source>Nature</source><year>2013</year><volume>497</volume><issue>7449</issue><fpage>392</fpage><lpage>6</lpage><comment>Epub 2013/04/26</comment><pub-id pub-id-type="pmid">23615615</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>K</given-names></name><name><surname>Ye</surname><given-names>G</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><etal/></person-group><article-title>RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak</article-title><source>Emerg Microbes Infect</source><year>2020</year><volume>9</volume><issue>1</issue><fpage>313</fpage><lpage>9</lpage><comment>Epub 2020/02/06</comment><pub-id pub-id-type="pmcid">PMC7033720</pub-id><pub-id pub-id-type="pmid">32020836</pub-id><pub-id pub-id-type="doi">10.1080/22221751.2020.1725399</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Harrison</surname><given-names>L</given-names></name><name><surname>Ramsden</surname><given-names>J</given-names></name><name><surname>Winter</surname><given-names>S</given-names></name><name><surname>Rocke</surname><given-names>J</given-names></name><name><surname>Heward</surname><given-names>E</given-names></name></person-group><source>Tracheostomy guidance during the COVID-19 Pandemic</source><publisher-name>ENT UK</publisher-name><year>2020</year><comment>Epub 2020/03/19</comment></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGrath</surname><given-names>BA</given-names></name><name><surname>Brenner</surname><given-names>MJ</given-names></name><name><surname>Warrillow</surname><given-names>SJ</given-names></name><name><surname>Pandian</surname><given-names>V</given-names></name><name><surname>Arora</surname><given-names>A</given-names></name><name><surname>Cameron</surname><given-names>TS</given-names></name><etal/></person-group><article-title>Tracheostomy in the COVID-19 era: global and multidisciplinary guidance</article-title><source>Lancet Respir Med</source><year>2020</year><volume>8</volume><issue>7</issue><fpage>717</fpage><lpage>25</lpage><comment>Epub 2020/05/19</comment><pub-id pub-id-type="pmcid">PMC7228735</pub-id><pub-id pub-id-type="pmid">32422180</pub-id><pub-id pub-id-type="doi">10.1016/S2213-2600(20)30230-7</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michetti</surname><given-names>CP</given-names></name><name><surname>Burlew</surname><given-names>CC</given-names></name><name><surname>Bulger</surname><given-names>EM</given-names></name><name><surname>Davis</surname><given-names>KA</given-names></name><name><surname>Spain</surname><given-names>DA</given-names></name><name><surname>Critical</surname><given-names>C</given-names></name><etal/></person-group><article-title>Performing tracheostomy during the Covid-19 pandemic: guidance and recommendations from the Critical Care and Acute Care Surgery Committees of the American Association for the Surgery of Trauma</article-title><source>Trauma Surg Acute Care Open</source><year>2020</year><volume>5</volume><issue>1</issue><elocation-id>e000482</elocation-id><comment>Epub 2020/05/06</comment><pub-id pub-id-type="pmcid">PMC7186881</pub-id><pub-id pub-id-type="pmid">32368620</pub-id><pub-id pub-id-type="doi">10.1136/tsaco-2020-000482</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parker</surname><given-names>NP</given-names></name><name><surname>Schiff</surname><given-names>BA</given-names></name><name><surname>Fritz</surname><given-names>MA</given-names></name><name><surname>Rapoport</surname><given-names>SK</given-names></name><name><surname>Schild</surname><given-names>S</given-names></name><name><surname>Altman</surname><given-names>KW</given-names></name><etal/></person-group><article-title>Tracheotomy recommendations during the COVID-19 pandemic</article-title><source>American Association of Otolaryngology-Head and Neck Surgery</source><year>2020</year></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>Z</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Kang</surname><given-names>L</given-names></name><name><surname>Ma</surname><given-names>W</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Genomic diversity of severe acute respiratory syndrome-coronavirus 2 in patients with coronavirus disease 2019</article-title><source>Clinical infectious diseases</source><year>2020</year><volume>71</volume><issue>15</issue><fpage>713</fpage><lpage>20</lpage><pub-id pub-id-type="pmcid">PMC7108196</pub-id><pub-id pub-id-type="pmid">32129843</pub-id><pub-id pub-id-type="doi">10.1093/cid/ciaa203</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiba</surname><given-names>T</given-names></name><name><surname>Ghazizadeh</surname><given-names>S</given-names></name><name><surname>Chhetri</surname><given-names>D</given-names></name><name><surname>St John</surname><given-names>M</given-names></name><name><surname>Long</surname><given-names>J</given-names></name></person-group><article-title>Tracheostomy Considerations during the COVID-19 Pandemic</article-title><source>OTO Open</source><year>2020</year><volume>4</volume><issue>2</issue><elocation-id>2473974X20922528</elocation-id><comment>Epub 2020/04/29</comment><pub-id pub-id-type="pmcid">PMC7175063</pub-id><pub-id pub-id-type="pmid">32342026</pub-id><pub-id pub-id-type="doi">10.1177/2473974X20922528</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sommer</surname><given-names>DD</given-names></name><name><surname>Engels</surname><given-names>PT</given-names></name><name><surname>Weitzel</surname><given-names>EK</given-names></name><name><surname>Khalili</surname><given-names>S</given-names></name><name><surname>Corsten</surname><given-names>M</given-names></name><name><surname>Tewfik</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Recommendations from the CSO-HNS taskforce on performance of tracheotomy during the COVID-19 pandemic</article-title><source>J Otolaryngol Head Neck Surg</source><year>2020</year><volume>49</volume><issue>1</issue><fpage>23</fpage><comment>Epub 2020/04/29</comment><pub-id pub-id-type="pmcid">PMC7184547</pub-id><pub-id pub-id-type="pmid">32340627</pub-id><pub-id pub-id-type="doi">10.1186/s40463-020-00414-9</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>YJ</given-names></name><name><surname>Okuda</surname><given-names>K</given-names></name><name><surname>Edwards</surname><given-names>CE</given-names></name><name><surname>Martinez</surname><given-names>DR</given-names></name><name><surname>Asakura</surname><given-names>T</given-names></name><name><surname>Dinnon III</surname><given-names>KH</given-names></name><etal/></person-group><article-title>SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract</article-title><source>Cell</source><year>2020</year><volume>182</volume><issue>2</issue><fpage>429</fpage><lpage>46</lpage><elocation-id>e14</elocation-id><pub-id pub-id-type="pmcid">PMC7250779</pub-id><pub-id pub-id-type="pmid">32526206</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2020.05.042</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sulaiman</surname><given-names>I</given-names></name><name><surname>Chung</surname><given-names>M</given-names></name><name><surname>Angel</surname><given-names>L</given-names></name><name><surname>Koralov</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>B</given-names></name><name><surname>Yeung</surname><given-names>ST</given-names></name><etal/></person-group><article-title>Microbial signatures in the lower airways of mechanically ventilated COVID19 patients associated with poor clinical outcome</article-title><source>Nature Microbiology</source><year>2021</year><volume>6</volume><fpage>1245</fpage><lpage>58</lpage><pub-id pub-id-type="pmcid">PMC8484067</pub-id><pub-id pub-id-type="pmid">34465900</pub-id><pub-id pub-id-type="doi">10.1038/s41564-021-00961-5</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oudit</surname><given-names>GY</given-names></name><name><surname>Crackower</surname><given-names>MA</given-names></name><name><surname>Backx</surname><given-names>PH</given-names></name><name><surname>Penninger</surname><given-names>JM</given-names></name></person-group><article-title>The role of ACE2 in cardiovascular physiology</article-title><source>Trends Cardiovasc Med</source><year>2003</year><volume>13</volume><issue>3</issue><fpage>93</fpage><lpage>101</lpage><comment>Epub 2003/04/15</comment><pub-id pub-id-type="pmid">12691672</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scozzi</surname><given-names>D</given-names></name><name><surname>Cano</surname><given-names>M</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>D</given-names></name><name><surname>Zhu</surname><given-names>JH</given-names></name><name><surname>O’Halloran</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Circulating mitochondrial DNA is an early indicator of severe illness and mortality from COVID-19</article-title><source>JCI Insight</source><year>2021</year><volume>6</volume><issue>4</issue><pub-id pub-id-type="pmcid">PMC7934921</pub-id><pub-id pub-id-type="pmid">33444289</pub-id><pub-id pub-id-type="doi">10.1172/jci.insight.143299</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shenoy</surname><given-names>S</given-names></name></person-group><article-title>Coronavirus (Covid-19) sepsis: revisiting mitochondrial dysfunction in pathogenesis, aging, inflammation, and mortality</article-title><source>Inflamm Res</source><year>2020</year><volume>69</volume><issue>11</issue><fpage>1077</fpage><lpage>85</lpage><comment>Epub 2020/08/09</comment><pub-id pub-id-type="pmcid">PMC7410962</pub-id><pub-id pub-id-type="pmid">32767095</pub-id><pub-id pub-id-type="doi">10.1007/s00011-020-01389-z</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caielli</surname><given-names>S</given-names></name><name><surname>Athale</surname><given-names>S</given-names></name><name><surname>Domic</surname><given-names>B</given-names></name><name><surname>Murat</surname><given-names>E</given-names></name><name><surname>Chandra</surname><given-names>M</given-names></name><name><surname>Banchereau</surname><given-names>R</given-names></name><etal/></person-group><article-title>Oxidized mitochondrial nucleoids released by neutrophils drive type I interferon production in human lupus</article-title><source>J Exp Med</source><year>2016</year><volume>213</volume><issue>5</issue><fpage>697</fpage><lpage>713</lpage><comment>Epub 2016/04/20</comment><pub-id pub-id-type="pmcid">PMC4854735</pub-id><pub-id pub-id-type="pmid">27091841</pub-id><pub-id pub-id-type="doi">10.1084/jem.20151876</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kerkmann</surname><given-names>M</given-names></name><name><surname>Rothenfusser</surname><given-names>S</given-names></name><name><surname>Hornung</surname><given-names>V</given-names></name><name><surname>Towarowski</surname><given-names>A</given-names></name><name><surname>Wagner</surname><given-names>M</given-names></name><name><surname>Sarris</surname><given-names>A</given-names></name><etal/></person-group><article-title>Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells</article-title><source>The Journal of Immunology</source><year>2003</year><volume>170</volume><issue>9</issue><fpage>4465</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">12707322</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neufeldt</surname><given-names>CJ</given-names></name><name><surname>Cerikan</surname><given-names>B</given-names></name><name><surname>Cortese</surname><given-names>M</given-names></name><name><surname>Frankish</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>J-Y</given-names></name><name><surname>Plociennikowska</surname><given-names>A</given-names></name><etal/></person-group><article-title>SARS-CoV-2 infection induces a pro-inflammatory cytokine response through cGAS-STING and NF-κB</article-title><source>BioRxiv</source><year>2020</year><pub-id pub-id-type="pmcid">PMC8755718</pub-id><pub-id pub-id-type="pmid">35022513</pub-id><pub-id pub-id-type="doi">10.1038/s42003-021-02983-5</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villarroya-Beltri</surname><given-names>C</given-names></name><name><surname>Baixauli</surname><given-names>F</given-names></name><name><surname>Mittelbrunn</surname><given-names>M</given-names></name><name><surname>Fernandez-Delgado</surname><given-names>I</given-names></name><name><surname>Torralba</surname><given-names>D</given-names></name><name><surname>Moreno-Gonzalo</surname><given-names>O</given-names></name><etal/></person-group><article-title>ISGylation controls exosome secretion by promoting lysosomal degradation of MVB proteins</article-title><source>Nat Commun</source><year>2016</year><volume>7</volume><issue>1</issue><fpage>13588</fpage><comment>Epub 2016/11/25</comment><pub-id pub-id-type="pmcid">PMC5123068</pub-id><pub-id pub-id-type="pmid">27882925</pub-id><pub-id pub-id-type="doi">10.1038/ncomms13588</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tissari</surname><given-names>J</given-names></name><name><surname>Siren</surname><given-names>J</given-names></name><name><surname>Meri</surname><given-names>S</given-names></name><name><surname>Julkunen</surname><given-names>I</given-names></name><name><surname>Matikainen</surname><given-names>S</given-names></name></person-group><article-title>IFN-alpha enhances TLR3-mediated antiviral cytokine expression in human endothelial and epithelial cells by up-regulating TLR3 expression</article-title><source>J Immunol</source><year>2005</year><volume>174</volume><issue>7</issue><fpage>4289</fpage><lpage>94</lpage><comment>Epub 2005/03/22</comment><pub-id pub-id-type="pmid">15778392</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Vries</surname><given-names>M</given-names></name><name><surname>Mohamed</surname><given-names>AS</given-names></name><name><surname>Prescott</surname><given-names>RA</given-names></name><name><surname>Valero-Jimenez</surname><given-names>AM</given-names></name><name><surname>Desvignes</surname><given-names>L</given-names></name><name><surname>O’Connor</surname><given-names>R</given-names></name><etal/></person-group><article-title>A comparative analysis of SARS-CoV-2 antivirals characterizes 3CLpro inhibitor PF-00835231 as a potential new treatment for COVID-19</article-title><source>J Virol</source><year>2021</year><volume>95</volume><issue>10</issue><fpage>e01819</fpage><lpage>20</lpage><pub-id pub-id-type="pmcid">PMC8139662</pub-id><pub-id pub-id-type="pmid">33622961</pub-id><pub-id pub-id-type="doi">10.1128/JVI.01819-20</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desmyter</surname><given-names>J</given-names></name><name><surname>Melnick</surname><given-names>JL</given-names></name><name><surname>Rawls</surname><given-names>WE</given-names></name></person-group><article-title>Defectiveness of interferon production and of rubella virus interference in a line of African green monkey kidney cells (Vero)</article-title><source>J Virol</source><year>1968</year><volume>2</volume><issue>10</issue><fpage>955</fpage><lpage>61</lpage><comment>Epub 1968/10/01</comment><pub-id pub-id-type="pmcid">PMC375423</pub-id><pub-id pub-id-type="pmid">4302013</pub-id><pub-id pub-id-type="doi">10.1128/jvi.2.10.955-961.1968</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mosca</surname><given-names>JD</given-names></name><name><surname>Pitha</surname><given-names>PM</given-names></name></person-group><article-title>Transcriptional and posttranscriptional regulation of exogenous human beta interferon gene in simian cells defective in interferon synthesis</article-title><source>Mol Cell Biol</source><year>1986</year><volume>6</volume><issue>6</issue><fpage>2279</fpage><lpage>83</lpage><comment>Epub 1986/06/01</comment><pub-id pub-id-type="pmcid">PMC367773</pub-id><pub-id pub-id-type="pmid">3785197</pub-id><pub-id pub-id-type="doi">10.1128/mcb.6.6.2279</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ke</surname><given-names>Z</given-names></name><name><surname>Oton</surname><given-names>J</given-names></name><name><surname>Qu</surname><given-names>K</given-names></name><name><surname>Cortese</surname><given-names>M</given-names></name><name><surname>Zila</surname><given-names>V</given-names></name><name><surname>McKeane</surname><given-names>L</given-names></name><etal/></person-group><article-title>Structures and distributions of SARS-CoV-2 spike proteins on intact virions</article-title><source>Nature</source><year>2020</year><volume>588</volume><issue>7838</issue><fpage>498</fpage><lpage>502</lpage><comment>Epub 2020/08/18</comment><pub-id pub-id-type="pmcid">PMC7116492</pub-id><pub-id pub-id-type="pmid">32805734</pub-id><pub-id pub-id-type="doi">10.1038/s41586-020-2665-2</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>HP</given-names></name><name><surname>Look</surname><given-names>DC</given-names></name><name><surname>Tan</surname><given-names>P</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Hickey</surname><given-names>M</given-names></name><name><surname>Gakhar</surname><given-names>L</given-names></name><etal/></person-group><article-title>Ectodomain shedding of angiotensin converting enzyme 2 in human airway epithelia</article-title><source>American Journal of Physiology-Lung Cellular Molecular Physiology</source><year>2009</year><volume>297</volume><issue>1</issue><fpage>L84</fpage><lpage>L96</lpage><pub-id pub-id-type="pmcid">PMC2711803</pub-id><pub-id pub-id-type="pmid">19411314</pub-id><pub-id pub-id-type="doi">10.1152/ajplung.00071.2009</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imai</surname><given-names>Y</given-names></name><name><surname>Kuba</surname><given-names>K</given-names></name><name><surname>Rao</surname><given-names>S</given-names></name><name><surname>Huan</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>F</given-names></name><name><surname>Guan</surname><given-names>B</given-names></name><etal/></person-group><article-title>Angiotensin-converting enzyme 2 protects from severe acute lung failure</article-title><source>Nature</source><year>2005</year><volume>436</volume><issue>7047</issue><fpage>112</fpage><lpage>6</lpage><pub-id pub-id-type="pmcid">PMC7094998</pub-id><pub-id pub-id-type="pmid">16001071</pub-id><pub-id pub-id-type="doi">10.1038/nature03712</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hassanpour</surname><given-names>M</given-names></name><name><surname>Rezaie</surname><given-names>J</given-names></name><name><surname>Nouri</surname><given-names>M</given-names></name><name><surname>Panahi</surname><given-names>Y</given-names></name></person-group><article-title>The role of extracellular vesicles in COVID-19 virus infection</article-title><source>Infect Genet Evol</source><year>2020</year><volume>85</volume><elocation-id>104422</elocation-id><comment>Epub 2020/06/17</comment><pub-id pub-id-type="pmcid">PMC7293471</pub-id><pub-id pub-id-type="pmid">32544615</pub-id><pub-id pub-id-type="doi">10.1016/j.meegid.2020.104422</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalamvoki</surname><given-names>M</given-names></name><name><surname>Du</surname><given-names>T</given-names></name><name><surname>Roizman</surname><given-names>B</given-names></name></person-group><article-title>Cells infected with herpes simplex virus 1 export to uninfected cells exosomes containing STING, viral mRNAs, and microRNAs</article-title><source>Proc Natl Acad Sci U S A</source><year>2014</year><volume>111</volume><issue>46</issue><fpage>E4991</fpage><lpage>6</lpage><comment>Epub 2014/11/05</comment><pub-id pub-id-type="pmcid">PMC4246290</pub-id><pub-id pub-id-type="pmid">25368198</pub-id><pub-id pub-id-type="doi">10.1073/pnas.1419338111</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saha</surname><given-names>B</given-names></name><name><surname>Kodys</surname><given-names>K</given-names></name><name><surname>Adejumo</surname><given-names>A</given-names></name><name><surname>Szabo</surname><given-names>G</given-names></name></person-group><article-title>Circulating and exosome-packaged hepatitis C single-stranded RNA induce monocyte differentiation via TLR7/8 to polarized macrophages and fibrocytes</article-title><source>The Journal of Immunology</source><year>2017</year><volume>198</volume><issue>5</issue><fpage>1974</fpage><lpage>84</lpage><pub-id pub-id-type="pmcid">PMC5322233</pub-id><pub-id pub-id-type="pmid">28122964</pub-id><pub-id pub-id-type="doi">10.4049/jimmunol.1600797</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>S</given-names></name><name><surname>Cortese</surname><given-names>M</given-names></name><name><surname>Winter</surname><given-names>SL</given-names></name><name><surname>Wachsmuth-Melm</surname><given-names>M</given-names></name><name><surname>Neufeldt</surname><given-names>CJ</given-names></name><name><surname>Cerikan</surname><given-names>B</given-names></name><etal/></person-group><article-title>SARS-CoV-2 structure and replication characterized by in situ cryo-electron tomography</article-title><source>Nature Communications</source><year>2020</year><volume>11</volume><issue>1</issue><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmcid">PMC7676268</pub-id><pub-id pub-id-type="pmid">33208793</pub-id><pub-id pub-id-type="doi">10.1038/s41467-020-19619-7</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reggiori</surname><given-names>F</given-names></name><name><surname>Monastyrska</surname><given-names>I</given-names></name><name><surname>Verheije</surname><given-names>MH</given-names></name><name><surname>Calì</surname><given-names>T</given-names></name><name><surname>Ulasli</surname><given-names>M</given-names></name><name><surname>Bianchi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Coronaviruses Hijack the LC3-I-positive EDEMosomes, ER-derived vesicles exporting short-lived ERAD regulators, for replication</article-title><source>Cell Host Microbe</source><year>2010</year><volume>7</volume><issue>6</issue><fpage>500</fpage><lpage>8</lpage><pub-id pub-id-type="pmcid">PMC7103375</pub-id><pub-id pub-id-type="pmid">20542253</pub-id><pub-id pub-id-type="doi">10.1016/j.chom.2010.05.013</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prentice</surname><given-names>E</given-names></name><name><surname>Jerome</surname><given-names>WG</given-names></name><name><surname>Yoshimori</surname><given-names>T</given-names></name><name><surname>Mizushima</surname><given-names>N</given-names></name><name><surname>Denison</surname><given-names>MR</given-names></name></person-group><article-title>Coronavirus replication complex formation utilizes components of cellular autophagy</article-title><source>Journal of Biological Chemistry</source><year>2004</year><volume>279</volume><issue>11</issue><fpage>10136</fpage><lpage>41</lpage><pub-id pub-id-type="pmcid">PMC7957857</pub-id><pub-id pub-id-type="pmid">14699140</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M306124200</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klionsky</surname><given-names>DJ</given-names></name><name><surname>Petroni</surname><given-names>G</given-names></name><name><surname>Amaravadi</surname><given-names>RK</given-names></name><name><surname>Baehrecke</surname><given-names>EH</given-names></name><name><surname>Ballabio</surname><given-names>A</given-names></name><name><surname>Boya</surname><given-names>P</given-names></name><etal/></person-group><article-title>Autophagy in major human diseases</article-title><source>EMBO</source><year>2021</year><volume>40</volume><issue>19</issue><elocation-id>e108863</elocation-id><pub-id pub-id-type="pmcid">PMC8488577</pub-id><pub-id pub-id-type="pmid">34459017</pub-id><pub-id pub-id-type="doi">10.15252/embj.2021108863</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>S</given-names></name><name><surname>Dellibovi-Ragheb</surname><given-names>TA</given-names></name><name><surname>Kerviel</surname><given-names>A</given-names></name><name><surname>Pak</surname><given-names>E</given-names></name><name><surname>Qiu</surname><given-names>Q</given-names></name><name><surname>Fisher</surname><given-names>M</given-names></name><etal/></person-group><article-title>β-Coronaviruses use lysosomes for egress instead of the biosynthetic secretory pathway</article-title><source>Cell</source><year>2020</year><volume>183</volume><issue>6</issue><fpage>1520</fpage><lpage>35</lpage><elocation-id>e14</elocation-id><pub-id pub-id-type="pmcid">PMC7590812</pub-id><pub-id pub-id-type="pmid">33157038</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2020.10.039</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayn</surname><given-names>M</given-names></name><name><surname>Hirschenberger</surname><given-names>M</given-names></name><name><surname>Koepke</surname><given-names>L</given-names></name><name><surname>Nchioua</surname><given-names>R</given-names></name><name><surname>Straub</surname><given-names>JH</given-names></name><name><surname>Klute</surname><given-names>S</given-names></name><etal/></person-group><article-title>Systematic functional analysis of SARS-CoV-2 proteins uncovers viral innate immune antagonists and remaining vulnerabilities</article-title><source>Cell Rep</source><year>2021</year><volume>35</volume><issue>7</issue><elocation-id>109126</elocation-id><comment>Epub 2021/05/12</comment><pub-id pub-id-type="pmcid">PMC8078906</pub-id><pub-id pub-id-type="pmid">33974846</pub-id><pub-id pub-id-type="doi">10.1016/j.celrep.2021.109126</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Zheng</surname><given-names>Q</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Ji</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Deng</surname><given-names>H</given-names></name><etal/></person-group><article-title>ORF3a of SARS-CoV-2 promotes lysosomal exocytosis-mediated viral egress</article-title><source>Developmental Cell</source><year>2021</year><pub-id pub-id-type="pmcid">PMC8502680</pub-id><pub-id pub-id-type="pmid">34706264</pub-id><pub-id pub-id-type="doi">10.1016/j.devcel.2021.10.006</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Javed</surname><given-names>R</given-names></name><name><surname>Mudd</surname><given-names>M</given-names></name><name><surname>Pallikkuth</surname><given-names>S</given-names></name><name><surname>Lidke</surname><given-names>KA</given-names></name><name><surname>Jain</surname><given-names>A</given-names></name><etal/></person-group><article-title>Mammalian hybrid pre-autophagosomal structure HyPAS generates autophagosomes</article-title><source>Cell</source><year>2021</year><pub-id pub-id-type="pmcid">PMC8616855</pub-id><pub-id pub-id-type="pmid">34741801</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2021.10.017</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>F</given-names></name><name><surname>Luo</surname><given-names>B</given-names></name><name><surname>Yuan</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The ORF8 protein of SARS-CoV-2 mediates immune evasion through down-regulating MHC-I</article-title><source>Proc Natl Acad Sci</source><year>2021</year><volume>118</volume><issue>23</issue><pub-id pub-id-type="pmcid">PMC8201919</pub-id><pub-id pub-id-type="pmid">34021074</pub-id><pub-id pub-id-type="doi">10.1073/pnas.2024202118</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stukalov</surname><given-names>A</given-names></name><name><surname>Girault</surname><given-names>V</given-names></name><name><surname>Grass</surname><given-names>V</given-names></name><name><surname>Karayel</surname><given-names>O</given-names></name><name><surname>Bergant</surname><given-names>V</given-names></name><name><surname>Urban</surname><given-names>C</given-names></name><etal/></person-group><article-title>Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV</article-title><source>Nature</source><year>2021</year><volume>594</volume><issue>7862</issue><fpage>246</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">33845483</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadowski</surname><given-names>L</given-names></name><name><surname>Pilecka</surname><given-names>I</given-names></name><name><surname>Miaczynska</surname><given-names>M</given-names></name></person-group><article-title>Signaling from endosomes: location makes a difference</article-title><source>Exp Cell Res</source><year>2009</year><volume>315</volume><issue>9</issue><fpage>1601</fpage><lpage>9</lpage><comment>Epub 2008/10/22</comment><pub-id pub-id-type="pmid">18930045</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zanin</surname><given-names>N</given-names></name><name><surname>Viaris de Lesegno</surname><given-names>C</given-names></name><name><surname>Lamaze</surname><given-names>C</given-names></name><name><surname>Blouin</surname><given-names>CM</given-names></name></person-group><article-title>Interferon Receptor Trafficking and Signaling: Journey to the Cross Roads</article-title><source>Front Immunol</source><year>2020</year><volume>11</volume><elocation-id>615603</elocation-id><comment>Epub 2021/02/09</comment><pub-id pub-id-type="pmcid">PMC7855707</pub-id><pub-id pub-id-type="pmid">33552080</pub-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.615603</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Majer</surname><given-names>O</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Kreuk</surname><given-names>LS</given-names></name><name><surname>Krogan</surname><given-names>N</given-names></name><name><surname>Barton</surname><given-names>GM</given-names></name></person-group><article-title>UNC93B1 recruits syntenin-1 to dampen TLR7 signalling and prevent autoimmunity</article-title><source>Nature</source><year>2019</year><volume>575</volume><issue>7782</issue><fpage>366</fpage><lpage>70</lpage><pub-id pub-id-type="pmcid">PMC6856441</pub-id><pub-id pub-id-type="pmid">31546246</pub-id><pub-id pub-id-type="doi">10.1038/s41586-019-1612-6</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asselin-Paturel</surname><given-names>C</given-names></name><name><surname>Trinchieri</surname><given-names>G</given-names></name></person-group><article-title>Production of type I interferons: plasmacytoid dendritic cells and beyond</article-title><source>J Exp Med</source><year>2005</year><volume>202</volume><issue>4</issue><fpage>461</fpage><lpage>5</lpage><comment>Epub 2005/08/17</comment><pub-id pub-id-type="pmcid">PMC2212850</pub-id><pub-id pub-id-type="pmid">16103406</pub-id><pub-id pub-id-type="doi">10.1084/jem.20051395</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Besse</surname><given-names>B</given-names></name><name><surname>Charrier</surname><given-names>M</given-names></name><name><surname>Lapierre</surname><given-names>V</given-names></name><name><surname>Dansin</surname><given-names>E</given-names></name><name><surname>Lantz</surname><given-names>O</given-names></name><name><surname>Planchard</surname><given-names>D</given-names></name><etal/></person-group><article-title>Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC</article-title><source>Oncoimmunology</source><year>2016</year><volume>5</volume><issue>4</issue><elocation-id>e1071008</elocation-id><comment>ARTN e1071008 . WOS:000374194200004</comment><pub-id pub-id-type="pmcid">PMC4839329</pub-id><pub-id pub-id-type="pmid">27141373</pub-id><pub-id pub-id-type="doi">10.1080/2162402X.2015.1071008</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>S</given-names></name><name><surname>Wei</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Wei</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer</article-title><source>Mol Ther</source><year>2008</year><volume>16</volume><issue>4</issue><fpage>782</fpage><lpage>90</lpage><comment>Epub 2008/03/26</comment><pub-id pub-id-type="pmcid">PMC7106337</pub-id><pub-id pub-id-type="pmid">18362931</pub-id><pub-id pub-id-type="doi">10.1038/mt.2008.1</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nassar</surname><given-names>W</given-names></name><name><surname>El-Ansary</surname><given-names>M</given-names></name><name><surname>Sabry</surname><given-names>D</given-names></name><name><surname>Mostafa</surname><given-names>MA</given-names></name><name><surname>Fayad</surname><given-names>T</given-names></name><name><surname>Kotb</surname><given-names>E</given-names></name><etal/></person-group><article-title>Umbilical cord mesenchymal stem cells derived extracellular vesicles can safely ameliorate the progression of chronic kidney diseases</article-title><source>Biomaterials Research</source><year>2016</year><volume>20</volume><issue>1</issue><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="pmcid">PMC4974791</pub-id><pub-id pub-id-type="pmid">27499886</pub-id><pub-id pub-id-type="doi">10.1186/s40824-016-0068-0</pub-id></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wüst</surname><given-names>S</given-names></name><name><surname>Schad</surname><given-names>P</given-names></name><name><surname>Burkart</surname><given-names>S</given-names></name><name><surname>Binder</surname><given-names>MJC</given-names></name></person-group><article-title>Comparative Analysis of Six IRF Family Members in Alveolar Epithelial Cell-Intrinsic Antiviral Responses</article-title><source>Cells</source><year>2021</year><volume>10</volume><issue>10</issue><fpage>2600</fpage><pub-id pub-id-type="pmcid">PMC8533862</pub-id><pub-id pub-id-type="pmid">34685580</pub-id><pub-id pub-id-type="doi">10.3390/cells10102600</pub-id></element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>A</given-names></name><name><surname>Negro</surname><given-names>C</given-names></name><name><surname>Bruhn</surname><given-names>JF</given-names></name><name><surname>Rice</surname><given-names>WJ</given-names></name><name><surname>Dallakyan</surname><given-names>S</given-names></name><name><surname>Eng</surname><given-names>ET</given-names></name><etal/></person-group><article-title>Leginon: New features and applications</article-title><source>Protein Sci</source><year>2021</year><volume>30</volume><issue>1</issue><fpage>136</fpage><lpage>50</lpage><comment>Epub 2020/10/09</comment><pub-id pub-id-type="pmcid">PMC7737759</pub-id><pub-id pub-id-type="pmid">33030237</pub-id><pub-id pub-id-type="doi">10.1002/pro.3967</pub-id></element-citation></ref><ref id="R59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suloway</surname><given-names>C</given-names></name><name><surname>Pulokas</surname><given-names>J</given-names></name><name><surname>Fellmann</surname><given-names>D</given-names></name><name><surname>Cheng</surname><given-names>A</given-names></name><name><surname>Guerra</surname><given-names>F</given-names></name><name><surname>Quispe</surname><given-names>J</given-names></name><etal/></person-group><article-title>Automated molecular microscopy: the new Leginon system</article-title><source>J Struct Biol</source><year>2005</year><volume>151</volume><issue>1</issue><fpage>41</fpage><lpage>60</lpage><comment>Epub 2005/05/14</comment><pub-id pub-id-type="pmid">15890530</pub-id></element-citation></ref><ref id="R60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>SQ</given-names></name><name><surname>Palovcak</surname><given-names>E</given-names></name><name><surname>Armache</surname><given-names>J-P</given-names></name><name><surname>Verba</surname><given-names>KA</given-names></name><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>Agard</surname><given-names>DA</given-names></name></person-group><article-title>MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy</article-title><source>Nature Methods</source><year>2017</year><volume>14</volume><issue>4</issue><fpage>331</fpage><lpage>2</lpage><pub-id pub-id-type="pmcid">PMC5494038</pub-id><pub-id pub-id-type="pmid">28250466</pub-id><pub-id pub-id-type="doi">10.1038/nmeth.4193</pub-id></element-citation></ref><ref id="R61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mastronarde</surname><given-names>DN</given-names></name></person-group><article-title>Automated electron microscope tomography using robust prediction of specimen movements</article-title><source>J Struct Biol</source><year>2005</year><volume>152</volume><issue>1</issue><fpage>36</fpage><lpage>51</lpage><comment>Epub 2005/09/27</comment><pub-id pub-id-type="pmid">16182563</pub-id></element-citation></ref><ref id="R62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tegunov</surname><given-names>D</given-names></name><name><surname>Cramer</surname><given-names>P</given-names></name></person-group><article-title>Real-time cryo-electron microscopy data preprocessing with Warp</article-title><source>Nat Methods</source><year>2019</year><volume>16</volume><issue>11</issue><fpage>1146</fpage><lpage>52</lpage><comment>Epub 2019/10/09</comment><pub-id pub-id-type="pmcid">PMC6858868</pub-id><pub-id pub-id-type="pmid">31591575</pub-id><pub-id pub-id-type="doi">10.1038/s41592-019-0580-y</pub-id></element-citation></ref><ref id="R63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galaz-Montoya</surname><given-names>JG</given-names></name><name><surname>Flanagan</surname><given-names>J</given-names></name><name><surname>Schmid</surname><given-names>MF</given-names></name><name><surname>Ludtke</surname><given-names>SJ</given-names></name></person-group><article-title>Single particle tomography in EMAN2</article-title><source>J Struct Biol</source><year>2015</year><volume>190</volume><issue>3</issue><fpage>279</fpage><lpage>90</lpage><comment>Epub 2015/05/10</comment><pub-id pub-id-type="pmcid">PMC4457691</pub-id><pub-id pub-id-type="pmid">25956334</pub-id><pub-id pub-id-type="doi">10.1016/j.jsb.2015.04.016</pub-id></element-citation></ref><ref id="R64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bepler</surname><given-names>T</given-names></name><name><surname>Morin</surname><given-names>A</given-names></name><name><surname>Rapp</surname><given-names>M</given-names></name><name><surname>Brasch</surname><given-names>J</given-names></name><name><surname>Shapiro</surname><given-names>L</given-names></name><name><surname>Noble</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Positive-unlabeled convolutional neural networks for particle picking in cryo-electron micrographs</article-title><source>Nat Methods</source><year>2019</year><volume>16</volume><issue>11</issue><fpage>1153</fpage><lpage>60</lpage><comment>Epub 2019/10/09</comment><pub-id pub-id-type="pmcid">PMC6858545</pub-id><pub-id pub-id-type="pmid">31591578</pub-id><pub-id pub-id-type="doi">10.1038/s41592-019-0575-8</pub-id></element-citation></ref><ref id="R65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mastronarde</surname><given-names>DN</given-names></name><name><surname>Held</surname><given-names>SR</given-names></name></person-group><article-title>Automated tilt series alignment and tomographic reconstruction in IMOD</article-title><source>J Struct Biol</source><year>2017</year><volume>197</volume><issue>2</issue><fpage>102</fpage><lpage>13</lpage><comment>Epub 2016/07/23</comment><pub-id pub-id-type="pmcid">PMC5247408</pub-id><pub-id pub-id-type="pmid">27444392</pub-id><pub-id pub-id-type="doi">10.1016/j.jsb.2016.07.011</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><title>ACE2+ exosomes are associated with reduced length of stay in ICU for COVID-19 patients.</title><p><bold>(A)</bold> Flow cytometry histograms of ACE2 levels on exosomes in BALF from 8 representative COVID-19 patients. Ctrl: isotype control on exosomes from non-covid patient BALF. <bold>(B)</bold> Correlation analysis of proportion of ACE2+ exosomes in BALF and length of stay in the ICU (<italic>N=78</italic>). Red dots indicate deaths. Simple regression analysis. <bold>(C)</bold> Correlation analysis of % ACE2 exosome levels with comorbidities colored: Hypertension (blue), Diabetes (green), both (orange). Red line indicates the average % of ACE2+ exosomes of all patients. <bold>(D)</bold> Length of stay in the ICU (blue), total hospitalization time (orange), and time on a ventilator (black) for each COVID patient (excluding deaths) plotted against the proportion of ACE2<sup>+</sup> exosomes isolated from BALF (<italic>N=59</italic>). r, Pearson correlation coefficient.</p></caption><graphic xlink:href="EMS161032-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><title>TLR ligands and SARS-CoV-2 induce exosome production.</title><p><bold>(A)</bold> Quantification of exosomes from A549 cell-culture supernatant by flow cytometry 16 hr after stimulation with 32 μg of oxidized mtDNA (ox mtDNA), mtDNA products without oxidized bases (non-ox mtDNA) or genomic DNA (gDNA) (<italic>n=4-10</italic>). <bold>(B)</bold> Quantification of exosomes from A549 cells stimulated for 16hr with 1μg/mL 3’3’-cGAMP (<italic>n=4</italic>), 2’3’-cGAMP (<italic>n=9</italic>), 0.5μM CpG-A (<italic>n=8</italic>), and 0.5μM CpG-B (<italic>n=7</italic>). CpG-A will be referred to as CpG from this point on. <bold>(C)</bold> Quantification of exosomes from A549 cells stimulated with various dilutions of IFN-β for 16hr (<italic>n=3-6</italic>). <bold>(D)</bold> Quantification of exosomes from A549 cells stimulated with various dilutions of IFN-λ for 16hr (<italic>n=3-6</italic>). <bold>(E)</bold> Quantification of exosomes following stimulation of A549 cells with 100U/mL IFNα for 16hr (<italic>n=5-9</italic>). <bold>(F)</bold> Exosome quantification of IFNAR/γR/λR triple KO (TKO) A549 cells stimulated with 500 U/mL IFN-β for 16hr compared to non-transduced (NT) A549 cells (<italic>n=7-11</italic>). <bold>(G)</bold> Quantification of exosomes from nontransduced (NT) A549 or TKO A549 cells stimulated with CpG for 16hr (<italic>n=3-6</italic>). <bold>(H)</bold> Quantification of exosomes from A549 cells stimulated with high or low molecular weight (HMW, LMW) Poly I:C with LyoVec at 50, 100, 500ng/mL (<italic>n=2-7</italic>). <bold>(I)</bold> Exosomes were quantified from A549 cells pretreated with 100U/mL IFNα for 24hr, followed by stimulation with 10μg/mL LMW or HMW PolyI:C. <bold>(J)</bold> Quantification of exosomes from A549 cells and TLR7 expressing A549 cells stimulated with 1μg/mL R848 for 16 hr. (<italic>n=3-5</italic>). <bold>(K)</bold> ACE2<sup>+</sup> A549 (NT) and ACE2<sup>+</sup> A549 cells knocked down for ATG16L1 using shRNA (ATG16L1 KD) were infected with TCID50 SARS-CoV-2 USA-WA1/2020 for 72 hrs. Exosomes were isolated from supernatants and quantified in exact counts (left) and fold change (right). <bold>(A-K)</bold>: Exosomes: CD9+ CD63+ CD81+ events. Measurements were taken from distinct samples. Error bars represent mean ± SEM and at least 2 independent experiments were performed. <bold>a,b,c,d,e,h,j</bold> One-way ANOVA with multiple comparisons with Dunnett’s post-test. <bold>f,g,i,k</bold> Two-way ANOVA using Dunnett’s post-test. * <italic>P</italic> ≤ 0.05; ** <italic>P</italic> ≤ 0.01; ns: not significant.</p></caption><graphic xlink:href="EMS161032-f002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><title>ACE2+ exosomes protect against SARS-CoV-2 infection.</title><p><bold>(A)</bold> Workflow for exosome neutralization assay used to assess protective effects of mixing SARS-CoV-2 and exosomes. Created with BioRender.com. <bold>(B)</bold> Representative histogram of cell-surface ACE2 on A549 and A549<sup>ACE2</sup> cells. <bold>(C)</bold> Representative immunofluorescence images of Vero E6 cells infected with SARS-CoV-2, pellet from 5000x<italic>g</italic> spin, ~20K exosomes from ACE2-cells, ~20K exosomes from ACE2+ cells, neutralizing antibody, or with media alone stained for viral N protein. <bold>(D)</bold> Percentage of infected Vero E6 cells based on positive staining for N protein after infection with SARS-CoV-2 mixed with exosomes isolated from A549<sup>ACE2</sup> (teal) or untransduced A549 cells (black). Compiled means ± SEM from 5 experiments, values normalized to infection with SARS-CoV-2 alone. <bold>(E)</bold> Representative immunofluorescence images of HAECs infected with mock (media only control), SARS-CoV-2 alone, ~11K (1) or ~22K (2) ACE2+ exosomes with virus, ~150K (3) ACE2-exosomes with virus, and neutralizing antibody with virus (nAb). Images were taken 72h.p.i. <bold>(F)</bold> Representative flow cytometry plots of exosomes isolated from Vero E6 cells stimulated with CpG. FSC: forward scatter, SSC: side scatter. <bold>(G)</bold> Quantification of exosomes from Vero E6 cells and Vero E6 cells transduced with a non-targeting shRNA for ATG16L1 stimulated with PBS (<italic>n=4</italic>) or 1uM CpG-A (<italic>n=4</italic>) for 16 hr. <bold>(H)</bold> Quantification of infected cells after infection of Vero E6 cells with SARS-CoV-2 only, SARS-CoV-2 mixed with supernatants of cells pretreated overnight with CpG-A (induced), or SARS-CoV-2 added to CpG-A pretreated cells following removal of supernatant (wash). Exosomes: CD9, CD63, CD81+, PKH67+ events. Means ± SEM of at least 2 independent experiments. <bold>g</bold> Two-way ANOVA with Dunnett’s post-test compared to NT PBS. <bold>h</bold> One-way ANOVA with Dunnett’s post-test compared to PBS. Error bars represent the mean ± SEM of at least 2 independent experiments, with measurements taken from distinct samples. ** <italic>P</italic> ≤ 0.01; **** <italic>P</italic> ≤ 0.0001. ns: not significant.</p></caption><graphic xlink:href="EMS161032-f003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><title>SARS-CoV-2 virions associate with ACE2+ exosomes.</title><p><bold>(A)</bold> Transmission electron microscopy (TEM) of negative stained exosomes and virus alone. Arrowheads: putative exosomes. Scale bars: 200nm. Red arrows mark the characteristic collapsing of exosomes during TEM imaging. <bold>(B)</bold> Double immunogold labeling TEM images of SARs-CoV-2 virions mixed with ACE2+ exosomes (right panel, scale bar: 50nm), or ACE2-exosomes (left panel). Virions are labeled using an antibody for SARS-CoV-2 N, followed by nanogold conjugated Fab (black triangle outline). Exosomes are labeled using an antibody against CD63, followed by 18nm colloidal gold conjugated IgG (filled white triangles). <bold>(C)</bold> Quantification of CD63 structures per virion present in a cluster containing both markers. ACE2+ (n=68 clusters), ACE2- (n=57). Mean ± SEM. Unpaired <italic>t</italic>-test with Welch’s correction. * <italic>P</italic> ≤ 0.05; ** <italic>P</italic> ≤ 0.01; *** <italic>P</italic> ≤ 0.001; **** <italic>P</italic> ≤ 0.0001. ns: not significant.</p></caption><graphic xlink:href="EMS161032-f004"/></fig><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Predictors of length of stay in the ICU among COVID-19 patients using a linear regression model.</title></caption><table frame="box" rules="all"><thead><tr><th align="center" valign="top" colspan="4" style="background-color:#000000"><styled-content style="color:#ffffff">Length of stay in ICU (Days)</styled-content></th></tr><tr><th align="left" valign="top" style="background-color:#d9d9d9">Predictors</th><th align="center" valign="top" style="background-color:#d9d9d9">Estimates</th><th align="center" valign="top" style="background-color:#d9d9d9">CI</th><th align="center" valign="top" style="background-color:#d9d9d9"><italic>P</italic> Value</th></tr></thead><tbody><tr><td align="left" valign="middle" style="background-color:#d9d9d9">Age (years)</td><td align="center" valign="middle" style="background-color:#d9d9d9">0.2338</td><td align="center" valign="middle" style="background-color:#d9d9d9">-0.5709 – 1.0385</td><td align="center" valign="middle" style="background-color:#d9d9d9">0.564</td></tr><tr><td align="left" valign="middle">% ACE2 positive (BAL exosomes)</td><td align="center" valign="middle">-0.549</td><td align="center" valign="middle">-0.7845 – -0.3136</td><td align="center" valign="middle">&lt;0.001</td></tr><tr><td align="left" valign="middle" style="background-color:#d9d9d9">Sex [M]</td><td align="center" valign="middle" style="background-color:#d9d9d9">39.7312</td><td align="center" valign="middle" style="background-color:#d9d9d9">-13.3973 – 92.8596</td><td align="center" valign="middle" style="background-color:#d9d9d9">0.14</td></tr><tr><td align="left" valign="middle">Hypertension</td><td align="center" valign="middle">12.1199</td><td align="center" valign="middle">-81.5270 – 105.7668</td><td align="center" valign="middle">0.797</td></tr><tr><td align="left" valign="middle" style="background-color:#d9d9d9">BAL <italic>C. albicans</italic> [Positive]</td><td align="center" valign="middle" style="background-color:#d9d9d9">21.05</td><td align="center" valign="middle" style="background-color:#d9d9d9">6.7861 – 35.3138</td><td align="center" valign="middle" style="background-color:#d9d9d9">0.004</td></tr><tr><td align="left" valign="middle">Blood culture final result [Positive]</td><td align="center" valign="middle">5.4402</td><td align="center" valign="middle">-3.8165 – 14.6968</td><td align="center" valign="middle">0.245</td></tr><tr><td align="left" valign="middle" style="background-color:#d9d9d9">(Intercept)</td><td align="center" valign="middle" style="background-color:#d9d9d9">50.0676</td><td align="center" valign="middle" style="background-color:#d9d9d9">2.4603 – 97.6750</td><td align="center" valign="middle" style="background-color:#d9d9d9">0.04</td></tr><tr><td align="left" valign="middle" style="background-color:#d9d9d9"><bold>Observations</bold></td><td align="center" valign="middle" style="background-color:#d9d9d9">78</td><td align="center" valign="middle" colspan="2" style="background-color:#d9d9d9"/></tr><tr><td align="left" valign="middle"><bold>R2 / R2 adjusted</bold></td><td align="center" valign="middle">0.375 / 0.281</td><td align="center" valign="middle" colspan="2"/></tr></tbody></table></table-wrap></floats-group></article>